Genetic heterogeneity in the African malaria mosquito, Anopheles gambiae, led to the recognition of chromosomal forms over 30 years ago by Prof Coluzzi and colleagues, who proposed that divergence between these populations was extensive and related to adaptation to mesic vs arid habitats as well as to particular types of larval habitats. Re-defi ned as "molecular forms, " genetic divergence among these populations has been elaborated by cutting-edge molecular studies, providing support for their status as distinct evolutionary units as well as against it, and fueling a lively debate that recently culminated in the elevation of the M and S forms to species, as A. coluzzii and A. gambiae, respectively. However, beyond geographical and seasonal observations, phenotypic diff erences between the forms have received far less attention. Surprisingly, minimal diff erences were found in adult body size, reproductive output, wet-season longevity, susceptibility to Plasmodium, desiccation resistance, and hightemperature tolerance; together, these results appear to undercut the implications of genetic divergence. Yet, evidence for diff erential predator-mediated developmental success of larvae supported adaptive divergence to distinct larval habitats, while additional studies showed that reproductive isolation across most of their ranges is maintained primarily by swarm segregation and possibly by withinswarm recognition based on fl ight pattern, sound, or chemical cues.
More recently, studies have revealed striking divergence in dry-season persistence strategies between Sahelian populations of these species. Accordingly, A. coluzzii persists through the dry season in situ, by a form of dormancy (aestivation), whereas A. gambiae recolonizes the area by wind-assisted long-distance migration. These results reveal profound ecological (behavioral and physiological) divergence between these populations, lending substantial support for their status as distinct species. Additionally, they affi rm Prof Coluzzi's insights about the evolutionary forces that have led to their speciation. Although these fi ndings provide strong clues as to the process of speciation in this complex, important gaps in this understanding remain, and hold promise for fresh scientifi c insights and for malaria control. One of the greatest challenges in reducing malaria transmission in sub-Saharan Africa is the high degree of plasticity in the behaviour and ecology of members of the Anopheles gambiae complex, which includes the most effi cient malaria vectors globally. For example, in areas of West Africa, sympatric populations of the M and S molecular forms of An. gambiae s.s. have diverged into recognized species (An. coluzzii Coetzee & Wilkerson sp.n. and the nominative species, An. gambiae s.s., respectively) through ecological speciation. Whereas the main breeding sites for An. gambiae s.s. continue to be temporary water bodies, An. coluzzii has become adapted to breeding well in irrigated fi elds, which has led to increases in relative abundance and duration of breeding seasons, and, hence, an enhancement of malaria transmission throughout the year. Thus, an increase in malaria prevalence is associated with a process of speciation that gave rise relatively rapidly to a new vector species highly adapted to a new breeding habitat created by changes in agricultural practice. To face this challenge, it is important that we understand the mechanisms by which this kind of speciation occurs. There is good evidence that speciation in this case has involved reproductive isolation, and, therefore, a fi ve year study of sympatric populations of the M and S molecular forms in the Bobo Dioulasso area of Burkina Faso was undertaken to identify mechanisms that limit cross-matings. Mating in the An. gambiae complex generally occurs in swarms consisting mainly of males, which form at specifi c times of day at consistent sites defi ned by physical features in the environment, e.g., over wells, piles of wood, clearings in vegetation. More than 1,000 mating swarms were documented; a measurable degree of reproductive isolation could be explained by signifi cant diff erences between species in seasonal abundance, characteristics of swarm sites and daily timing (circadian rhythm) of swarming. Although these factors each contribute to a reduced likelihood that males and females of 'opposite' molecular form encounter each other at close range in a mating swarm, both species were occasionally found in mixed swarms. All of the females caught in mixed swarms, however, had been inseminated by a conspecifi c male. Hence, further research is required to establish the close-range mechanism(s) of species recognition that seem to occur within swarms, such as auditory communication, that lead to assortative mating.
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Mechanisms of reproductive isolation between incipient species in the
Glucose-6-phosphate dehydrogenase (G6PD) defi ciency tests play a critical role in supporting the safe treatment and elimination of malaria. Evaluating G6PD activity in those infected with Plasmodium vivax will be essential in order to treat and achieve radical cures. Our goal is to establish a unique specimen repository with cryopreserved specimens highly characterized for G6PD activity. Providing such specimens to designers of G6PD point-of-care tests, will support both the development and evaluation of new diagnostic devices. Because G6PD-defi ciency prevalence ranges from <1->15%, obtaining fresh blood specimens with a range of levels of G6PD activity -as well as specimens from heterozygous females -typically requires constant screening from large numbers of subjects. Thus, developers would highly benefi t by using the same panel of specimens from the repository over the entire course of the development of a specifi c G6PD test. Currently the repository constitutes specimens from adults of known G6PD-defi cient population groups and will be expanded over time with diverse ethnic backgrounds. Standard operation procedures and formulations have been optimized to allow cryopreservation of red blood cells (RBC) and stabilize G6PD enzyme activity within the RBC. Flow cytometry and kinetic assays demonstrate that specimens can be stored a minimum of six months under these optimized conditions. Critically, thawed specimens demonstrate stability for seven days. We are using Freezerworks database to maintain the chain of custody of all specimens. Cytochemical staining is performed to pedigree the specimens. The specimens are processed and tested for G6PD activity immediately by quantitative and qualitative assays. Samples are stored depending on the phenotype in order to increase the capacity of G6PD diverse specimens. Samples with normal G6PD activity are more prevalent and discarded to accommodate intermediate and defi cient specimens. Once samples have been tested and selected for the repository, three preservation methods are used: (1) whole RBCs are cryopreserved in glycerolyte and stored in liquid nitrogen for G6PD phenotyping, (2) whole RBCs without glycerolyte are preserved in liquid nitrogen for phenotyping, and (3) peripheral mononuclear blood cells are preserved for DNA sequencing and genotyping. The G6PD specimen repository at PATH will provide a low-cost service to research, commercial, and other organizations with compatible product development goals that benefi t the global health community.
Mathematical modeling can serve to inform strategies for malaria eradication from diff erent levels of scale depending on the needs of the strategy and the granularity of the data available to create the models. At the most granular level of data, estimates of individual dose-eff ect relationships for anti-malarial drugs and vaccines can be used to simulate the impact of diff erent implementation strategies for administration and estimate the resulting impact of the therapeutic on disease treatment and transmission reduction. Coupled with epidemiological models that simulate the overall impact on disease prevalence across broad geometries, these tools can become important in planning at a regional level the appropriate response to eradicating malaria. Simplifying assumptions that make the modeling tractable can also limit its usefulness however, as understanding not only the human transmission aspect of the disease but also the vector transfer, the role of underlying geography and weather on vector movement, and the interactions of humans across space and time is important for realistic estimates of strategy impact through modeling. An iterative approach is needed where models predict the impact of an approach, the approach is attempted, the results are fed back to update the model in an iterative way, and new estimates are produced. Through this eff ort, models of malaria eradication can be important tools in guiding disease eradication.
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Age-shifting in malaria incidence upon cessation of interventions: a simulation study Peter Pemberton-Ross Background Malaria disease shifts to older ages when interventions are applied only to the youngest children, and incidence will resurge in endemic settings when intervention coverage decreases. This has consequences for the deployment of long-lasting insecticide treated nets or infection blocking vaccines (e.g. pre-erythrocytic vaccines). These delay acquisition of immunity, with the result that previously protected individuals may experience pathology later in life due to undeveloped or waning immunity. Here we use a mathematical model to investigate the long-term population impact and cost-eff ectiveness of new interventions and address the reasons rebounds are observed in models when interventions are not renewed and relate to observations from fi eld trials. Materials and methods The age and magnitude of age-and timeshifting of incidence is investigated using an ensemble of individualbased stochastic simulation models of Plasmodium falciparum dynamics, with varied assumptions about immunity decay, transmission heterogeneity, and access to treatment. The impact of transmission intensity, levels of access to malaria treatment and primary levels of intervention coverage and intervention profi le are also considered. The main drivers of shifts in incidence are determined, examining model assumptions of age incidence, immunity, and initial exposure. The likely onset and duration of excess events in a treated cohort compared to a control is also examined for specifi c intervention profi les. Results In the absence of new interventions, or the redistribution of current interventions, we fi nd that the underlying absence or loss of immunity resulting from previous lack of exposure is a primary driver of shifting of disease burden to older age groups. The simulations suggest that with short half-life interventions (~1 year), excess cases in the intervened cohort may be seen as soon as 3-4 years after intervention cessation. An excess of severe disease occurs sooner than one of uncomplicated disease, and sooner in high transmission areas than in low transmission areas. Because of slow build-up of natural immunity, excess incidence may be distributed over a long period after intervention cessation, making it unlikely that this will be detectable in fi eld studies. Conclusions This has important consequences for the design of transient interventions, in terms of both duration and demographics of deployment. Eff ective interventions will lead to initial decreases in malaria cases in a population, but these can be lost -or worse, redistributed in time and magnifi ed in number and impact, without sustained eff orts to decrease transmission.
severe and fatal outcomes. Early diagnosis and appropriate treatment interrupts progression and cures disease. Confi rmation of diagnosis of malaria currently relies on microscopy, or on application of rapid diagnostic tests (RDTs) that are becoming increasingly widely available and are recommended to confi rm infection before treating it. The diagnosis of malaria by itself is not suffi cient to optimise individual therapies because there is a growing problem of multidrug resistance in parasites (particularly Plasmodium falciparum). This limits the use of some drugs or combinations by severely compromising their effi cacy. Diagnostic strategies for management of malaria can therefore be improved in several ways. First by an increase in sensitivity of detection of parasites that should improve of the thresholds for detection by the current generation of RDTs because they cannot identify low parasitaemias. Second, a diagnostic that can diff erentiate all the naturally infecting species of parasite needs to be developed. Finally, rapid (point-of-care) assessment of the drug resistance status of parasites will add greatly to the treatment strategies available to manage individual patients. Technological platforms that can deliver information that is currently missing for the personalised management of malaria infections are being developed and these advances will be presented and discussed in the context of the global burden of disease caused by malaria.
The effi cacy of ACT for treating malaria patients infected with Plasmodium falciparum may be threatened by parasites with reduced responsiveness to artemisinins. Among 298 ACT-treated children from Mbita, Kenya, sub-microscopic persistence of P. falciparum on day 3 post-treatment was associated with subsequent microscopically detected parasitaemia at days 28 or 42. Parasite density post-treatment was measured by duplex probe qPCR at days 1, 2 and 3. DNA sequences of resistance-associated parasite loci pfcrt, pfmdr1, pfubp1 and pfap2mu were determined in the Mbita cohort before treatment, on days 2 and 3 after initiation of treatment and on the day of treatment failure. Among 298 ACT-treated children from Mbita, Kenya, sub-microscopic persistence of P. falciparum on day 3 post-treatment was associated with subsequent microscopically detected parasitaemia at days 28 or 42. Parasites surviving ACT on day 2 or day 3 post-treatment were signifi cantly more likely than the baseline population to carry the wildtype haplotypes of pfcrt (CVMNK at codons 72-76; P < 0.001) and pfmdr1 (NFD at codons 86, 184, 1246; P < 0.001). In contrast, variant alleles of the novel candidate resistance genes pfap2mu (S160N/T; P = 0.006) and pfubp-1 (E1528D; P < 0.001) were signifi cantly more prevalent post-treatment. No genetic similarities were found to parasites with reduced sensitivity to short-course artemisinin monotherapy, recently described in Cambodia. We conclude that, among treated children in western Kenya, certain multi-locus P. falciparum genotypes are more likely to survive ACT at sub-microscopic level, and contribute to onward transmission and subsequent patent recrudescence. These surviving parasites may have an important public health impact that has been overlooked. The possible role of both innate and acquired immune mechanisms in this phenomenon will be discussed. With an estimated two-thirds of children being aff ected, childhood anaemia causes poor cognitive development, reduced growth and impaired immune functions associated with increased mortality. In malaria-endemic regions, particularly in those with perennial Plasmodium falciparum transmission, most of the childhood anaemia disease burden is being attributed to malaria. The pathogenesis of malaria anaemia, which may well be the single most frequent cause for childhood mortality worldwide, has been debated for many decades. Materials and methods In order to identify underlying mechanisms for malaria anaemia two studies were evaluated: a cohort study including 465 children that were followed weekly over eight months and a severe malaria case-control study including >4,500 children, both carried out in a hyperendemic malaria area of Ghana, West Africa. Human genetic polymorphisms of candidate genes were genotyped and tested for association with malaria anaemia in both studies. Results We found several genotype-phenotype associations, which had diff ering eff ects after stratifying for anaemia with and without complications. For instance, uncomplicated anaemia was found associated with the A allele of rs196854, which was associated previously with an increased expression of interleukin-6, a key mediator of the systemic infl ammatory response. Conclusions Our results suggest that there are at least two diff erent underlying mechanisms of malaria anaemia, uncomplicated anaemia characterized by a slow and continuous development towards a defi cit of red blood cells, and anaemia with complications characterized by a rapid and substantial loss of red blood cells. The uncomplicated form appears to be caused by chronic systemic infl ammatory processes rather than malaria episodes or parasite densities, similar to what is found in other forms of anaemia of chronic disease (ACD). Plasmodium vivax merozoite invasion of reticulocytes is a rapid process that involves a series of specifi c, sequential interactions. These interactions are crucial for invasion and continued blood-stage infection, thus representing attractive targets for vaccine development. The Duff y binding protein (DBP) is a vital microneme protein associated with the decisive, irreversible step of junction formation during the later stages of the invasion process. The ligand domain of DBP, known as region II (DBPII), binds the Duff y Antigen Receptor for Chemokines (DARC) by dimerization of two DBP and two DARC molecules forming a heterotetrameric structure. Naturally acquired antibodies to DBPII are prevalent in residents of areas where vivax malaria is endemic. These antibodies can inhibit DBPII binding and merozoite invasion of human reticulocytes; however, they tend to be poorly inhibitory, strain-specifi c, and short-lived. Remarkably, strain-specifi c serologic activity can be altered by even single amino acid substitutions found in allelic variants of DBPII. While strain-transcending, broadly neutralizing antibodies are less prevalent, there is a signifi cant correlation of their antibody reactivity to certain epitopes and inhibition of DBPII-receptor function. Our data indicate epitopes at or near the dimer interface of DBPII represent the primary targets of naturally occurring protective anti-DBPII antibodies that can inhibit merozoite invasion of host erythrocytes. However, these epitopes also contain most of the prevalent variable residues resulting from DBP allelic diversity. These data are consistent with the hypothesis that DBP variation is an immune evasion mechanism responsible for strain-specifi c immunity and stable, broadly neutralizing immunity is achieved when antibodies target Malaria Journal 2014, Volume 13 Suppl 1 http://www.malariajournal.com/supplements/13/S1 S5 functionally-conserved epitopes, thereby blocking DBP dimerization and inhibiting invasion. To overcome the natural tendency for eliciting a strain-specifi c response, synthetic DBPII alleles were evaluated for their ability to broaden effi cacy of strain-transcending inhibition against diverse DBPII alleles. In an eff ort to identify potential conserved, protective epitopes we have prepared and evaluated a panel of anti-DBPII murine monoclonal antibodies. Inhibitory activities of these monoclonal antibodies were characterized with in vitro functional assays for DBPII and their respective minimal epitopes were mapped using phage display. These targets of putative strain-transcending inhibition identify epitopes that may be targeted for vaccine-induced anti-DBPII inhibitory antibodies. Perhaps the most daunting challenge for eliminating malaria is developing novel interventions to eradicate the dormant hypnozoite of Plasmodium vivax. New in vitro models are urgently needed to accelerate drug and vaccine discovery for liver stages of P. vivax malaria, yet maintaining the physiology of primary hepatocytes in long-term culture in vitro remains a major obstacle. Several advanced liver models support hepatic phenotypes necessary for drug and disease studies, yet these models are characterized by intricate features such as co-culture with one of more supporting cell types or advanced media perfusion systems. Regardless of the culture system, primary hepatocyte culture systems suff er from reproducibility issues due to phenotypic variation and expensive, limited supplies of donor lots. We have developed a microfl uidic bilayer device that sustains primary human hepatocyte phenotypes, including albumin production, factor IX production, cytochrome P450 3A4 drug metabolism and bile canaliculi formation for weeks in a simple monoculture format with static media. Using a variety of channel architectures, we discovered how primary cell phenotype is promoted by spatial confi nement within the microfl uidic channel, without the need for perfusion or co-culture. This new model is amenable to 384 well screening platforms and utilizes a few hundred primary human hepatocytes, maintains hepatocyte function for weeks in vitro within a relatively simple model, and addresses many of the major hurdles in human hepatocyte culture research. P.vivax was detected by PCR in 45% of children aged 5-10 years from our study area in Papua New Guinea (PNG). 504 children were randomized into 2 arms according to Primaquine (PQ) treatment or not at baseline and actively and passively followed for 9 months. We genotyped all P. vivax infections, the majority of these being multi-clone infections. As the high deformability of P. vivax facilitates its escaping from the splenic clearance, we hypothesize that CQ and AS directly aff ect the P. vivax infected red blood cells (iRBCs) rigidity. As a consequence, parasites are rapidly cleared from the blood circulation. Materials and methods P. vivax isolates from Thailand were pulse incubated with AS, CQ and a spiroindolone (NITD609). Morphological changes and rosetting frequency were assessed by sub vital staining. The micropipette aspiration technique was the used to quantify the cell membrane shear modulus. Microfl uidics were used to study the in vitro iRBCs behaviour after drug treatment.
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Dynamics of
Results While CQ and AS did not directly aff ect iRBC shear modulus, it signifi cantly enhanced rosetting frequency and consequently the rigidity of rosetted iRBCs (the attachment of a single red cell results in a signifi cant increase in shear modulus of the iRBC). NITD609 directly aff ected the iRBC rigidity. A microfl uidic model of the spleen shows that P. vivax iRBCs with a higher rigidity are removed from fl ow. This study also show that normocytes that rosette with P. vivax iRBCs; form strong attachments (~500pN) that withstand a range of physiological shear stresses.
Conclusions In addition to providing new and important baseline biomechanical data on P. vivax rosettes; this ex vivo study also provides a possible explanation for the clinically observed disappearance of P. vivax parasites soon after treatment.
of transmission between humans and mosquitoes, the balance between accurate measurement, suffi cient detail to inform program decisions, and ease and simplicity of information collection, analysis and interpretation has always been challenging. A summary of historic and current eff orts to measure parasites within and moving between people and mosquitoes will be provided with an emphasis on how the approaches and emphasis change as transmission intensity changes. The program decision needs for routine systems and for special studies to track transmission reduction will be discussed. The detection and verifi cation of "zero" infection and transmission will be discussed in terms of tools and sampling methods that will allow the designation of malaria-free areas. As global investments to combat malaria have reached over 1.8 billion per year, there is a strong desire by governments and donors to measure the number of deaths prevented from these investments. Much of this funding has gone to African countries where malaria burden is highest, but robust health information systems and vital registration are weakest, which precludes measuring changes in malaria deaths directly. Because malaria accounts for a large proportion of deaths in Africa (15%), assessing trends in all-cause child mortality (ACCM) has become a key indicator for measuring program impact. The objectives of this talk will be to provide a comparison of common epidemiological approaches used for evaluating the impact of malaria control programs on ACCM in the African context. Three examples of impact evaluation approached using ACCM as the primary outcome will be discussed: 1) comparison of ACCM measured by household surveys before and after malaria program introduction or scale-up (aka 'trends over time'); 2) assessment of the association between exposure to malaria control interventions (e.g. insecticide-treated mosquito nets-ITNs) and ACCM using cross-sectional data; and 3) an analytic frameworks that allow a dose-response relationships to be estimated between changes in subnational (district) malaria program intensity and ACCM. In doing so, an attempt will be made to discuss the key challenges of using these methods, as well as specifi c recommendations for their improvement. Insecticide-treated nets (ITNs), which comprise conventional (cITNs) and long-lasting insecticidal nets (LLINs), are the most widely used intervention for malaria control in Africa today. At least 700 million such nets have been fi nanced and delivered to countries since the onset of the Roll Back Malaria (RBM) partnership at the turn of the millennium, but coverage remains inadequate. Better understanding of how and why these volumes of net deliveries translate into the levels of access and use seen in households across Africa could improve the monitoring of coverage indicators, highlight opportunities for systematic effi ciency gains, and allow more accurate assessment of resources needed to meet international targets. We used a simple compartmental model to represent the system linking ITN deliveries to countries, distribution to households, and resulting coverage at the national level. We assembled coverage data from 93 national surveys representing 861,000 households between 2000 and 2013 and triangulated these against yearly ITN manufacturer delivery data and national malaria control programme ITN distribution reports for 44 sub-Saharan countries. We fi tted the model to these data using Bayesian inference with minimal prior assumptions.
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Insecticide-treated nets (ITNs) in
We present contemporary estimates of LLIN coverage for all endemic African countries since the year 2000. We then explore the impact of two potential ineffi ciencies: uneven net distribution between households and rapid rates of net loss from households. These factors substantially reduce the levels of coverage achieved relative to the volume of LLINs fi nanced and delivered, but are not fully captured in current approaches to calculating LLIN needs. Using these inferences, we estimate the levels of coverage achievable with diff ering volumes of LLIN provision by 2016 under various scenarios of current or modifi ed future levels of distributional effi ciency and retention by households.
Despite dramatic gains, current levels of ITN access and use remain well below international targets. Unless ineffi ciencies due to uneven distribution and rapid net loss can be addressed, meeting international targets will require substantially more nets than currently assumed.
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Towards a multi-antigen multi-stage malaria vaccine Adrian V S Hill, Sumi Biswas, Simon Draper, Thomas Rampling, Arturo Reyes-Sandoval University of Oxford, UK Malaria Journal 2014, 13(Suppl 1):O31
A highly eff ective malaria vaccine is a major goal of global health research and will likely require a multi-stage product. Oxford researchers are developing the concept of a highly eff ective multistage P. falciparum vaccine to the point of proof-of-concept phase II testing in Europe, prior to trials in malaria-endemic areas. Remarkable recent advances in vaccine design for all four stages of the P. falciparum parasite's life-cycle allow testing of a multi-stage multi-component vaccine for the fi rst time, with strong chances of success. These advances are i) the availability of a new vectored prime-boost vaccination regime based on the chimpanzee adenovirus technology that has been found to induce exceptionally potent CD8 + T cell responses and high titre antibodies against multiple malaria antigens; ii) the development of an improved virus-like particle (VLP) version of the leading partially protective RTS,S sporozoite vaccine candidate, termed R21, that lacks the excess of HBsAg in RTS,S; iii) the identifi cation, using a vector technology screen, of the blood-stage antigen RH5 as the fi rst antigen to induce potent strain-transcending neutralization of blood-stage parasites in in vitro growth inhibition assays; and iv) the demonstration that antibodies against a mosquitostage antigens that induce 100% transmission blocking against fi eld isolates of P. falciparum in Africa are inducible by a new nanoparticle vaccine candidate. In parallel similar approaches using vectors and VLPs are underway to target the pre-erythrocytic stages of P.vivax, including the hypnozoite, and a phase I trial of the vivax blood-stage vaccine candidate, PvRII, is nearing completion. We are aiming to undertake phase I/II clinical trials to assess the P.falciparum pre-erythrocytic, blood-stage and mosquito-stage components individually, and then together, using state-of-the art immunomonitoring, key functional assays of vaccine-induced immunogenicity, and sporozoite and blood-stage parasite challenges to measure effi cacy prior to fi eld testing. An update on this programme will be presented. A viral vectored prime-boost regime has recently shown high effi cacy against malaria infection in East Africa and the fi rst combination trial of RTS,S/AS01 with these vectors has been completed. The prospects for achieving high effi cacy with such combination approaches now appear very good.
(CHMI) and has proved to be a reproducible, predictable and safe method of inducing Plasmodium falciparum (Pf ) malaria. An effi cient method for induction of complete protection in humans was achieved by us in a CHMI setting by exposing human subjects to Pf-infected mosquitoes while taking blood-stage suppressive chloroquine prophylaxis. When tested in clinical trials, this protocol induced clinical and parasitological protection against a standard homologous and heterologous CHMI. In addition, we showed that CPS-induced protection was long lasting and primarily mediated by immunity to sporozoite and liver stages rather than to asexual blood-stages. Cellular responses to Plasmodium falciparum parasites, in particular interferongamma (IFNγ) production, CD107a CD4 cells and Granzyme producing CD8 cells, play an important role in anti-malarial immunity.
Our approach appears to utilize the Pf parasite's clinically salient replicative phase of liver stage development to induce fully protective immune response against sporozoites and liver stages. It opens opportunities to explore mechanisms of protective immunity, allowing the search for immune correlates/signatures of protection and clinical development of a whole sporozoite based vaccine.
Background Controlled human malaria infection (CHMI) studies, where healthy volunteers are infected with Plasmodium falciparum have become a vital tool to accelerate vaccine and drug development. As CHMI trials are carried out in a controlled environment, they allow unprecedented, detailed evaluation of parasite growth dynamics and immunological responses to infection. Though commonly performed in malaria-naïve populations, CHMI trials have rarely been performed in malaria endemic regions, despite the advantages of early testing of candidate anti-malaria vaccines and drugs in populations where malaria is endemic. To date, modern CHMI studies have not been used to investigate mechanisms of naturally acquired immunity (NAI) to P. falciparum infection.
Materials and methods
We conducted an open label, randomized CHMI pilot study using aseptic, cryopreserved P. falciparum sporozoites (PfSPZ Challenge) administered intramuscularly to evaluate safety, infectivity and parasite growth dynamics in healthy Kenyan adults (n = 28). We included adults with varying degrees of prior exposure to malaria in order to allow an evaluation of the eff ect of NAI on parasite growth dynamics post CHMI. Results All participants developed blood-stage infection, with a similar safety profi le to that observed in northern CHMI centres. One volunteer remained asymptomatic and blood-fi lm negative until day 21 post injection of PfSPZ Challenge, despite developing confi rmed bloodstage infection by quantitative polymerase chain reaction (qPCR). This volunteer had a notably reduced parasite multiplication rate (1.3) in comparison to the other 27 volunteers (median 11.1). A signifi cant correlation was seen between parasite multiplication rate (PMR) and anti-schizont ELISA OD at screening (P = 0.044).
Conclusions Our study has shown that the PfSPZ Challenge is safe and infectious in malaria endemic populations and could be used to aid early assessment of the effi cacy of candidate malaria vaccines and drugs in African populations. Whilst our fi ndings are limited by sample size, our pilot study proves that NAI can impact on PMR post-CHMI in a detectable fashion. Our fi ndings suggest the CHMI sporozoite model could allow identifi cation of a heterogeneous group of participants with varying degrees of NAI for whom the relationship between PMR and candidate assays of blood-stage immunity can be examined to try to gain greater understanding of the mechanisms of NAI to P. falciparum malaria. Sanaria® PfSPZ Vaccine is composed of aseptic, purifi ed, cryopreserved, attenuated (non-replicating), metabolically active Plasmodium falciparum (Pf ) sporozoites (SPZ) produced in compliance with good manufacturing practices (GMPs) that meet all regulatory standards. This vaccine provided full protection against Pf infection in 100% (6/6) volunteers, who received fi ve doses of 1.35 × 10 5 PfSPZ administered intravenously in a study at the Vaccine Research Center (VRC), NIAID, NIH [1] . Based on these data, the PfSPZ Vaccine Clinical Consortium composed of investigators from USA, Africa, and Europe has developed a four stage clinical development plan (CDP) that maps out a 4-5 year timeline to licensure and a large scale demonstration project to eliminate malaria from an island population in Africa. In 2014, six diff erent clinical trials of PfSPZ Vaccine at seven clinical sites in the United States (Bethesda, Baltimore, Silver Spring), Mali, Tanzania, Equatorial Guinea, and Germany will be underway. These six clinical trials, which include >450 subjects, comprise Stage 1 of the four stage PfSPZ Vaccine CDP. They are designed to 1) assess the reproducibility of the data generated in the VRC study and 2) assess and optimize durability of protection, protection against heterologous strains of Pf, reduction in numbers of doses, immune assays that predict protection, implementation of immunization, and alternative route of administration. We will provide an update of these stage 1 clinical trials and plans for stage 2 studies that will address questions required for progressing to pivotal phase 3 clinical trials in stage 3, and to demonstration projects for focal elimination in small populations. Reference populations especially those with more persons having G6PD defi ciency. Primaquine and methylene blue are among our oldest antimalarial drugs and are established means of killing the gametocyte transmission stages. Adverse events and long dosage regimens make both primaquine and methylene blue far from the mass drug administration model used during antifi larial drug campaigns. A long acting primaquine analog, tafenoquine, is in late clinical trials and may have some role in eliminating relapsing malaria hypnozoites from a population. Other new chemical compounds such as the imidazolepiperazine KA156 are in the development pipeline which have antitransmission potential although this has not be demonstrated in fi eld trials to date. Eliminating malaria will require a multi-faceted approach that will necessarily involve new means of using drugs to kill small residual parasite populations long after the major public health eff ects of malarial disease has disappeared.
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A fi rst-in-human randomized, double-blind, placebo-controlled, single-and multiple-ascending oral dose study of novel spiroindolone KAE609, to assess the safety, tolerability and pharmacokinetics in healthy adult volunteers Joel Leong Background New antimalarials are needed to address the threat of emerging artemisinin resistance. KAE609 is a spirotetrahydro-β-carbolines (spiroindolone) derivative and the fi rst molecule of this new class entering phase II studies. Materials and methods This fi rst in human randomized, double-blind, placebo-controlled, ascending single and multiple oral dose study was designed to evaluate the safety, tolerability and pharmacokinetics of KAE609 in healthy volunteers. The study comprised of single ascending dose (1-300 mg, including one 30 mg food eff ect cohort, with 4-10 subjects in each cohort) and multiple ascending dose (10-150 mg once daily for 3 days with 8 subjects in each cohort) cohorts. The follow-up period was 6-8 days post last dose. Safety and pharmacokinetics were assessed at scheduled time points during the study. Results Of the total 95 male subjects enrolled, 93 completed the study. Participants in both cohorts had comparable demographics. Systemic exposure in terms of AUC inf increased in a dose-proportional manner over the dose range of 1-300 mg. AUC last and C max also increased in an approximately dose-proportional manner in single and multiple dose cohorts respectively, though not considered statistically doseproportional. When administered daily for three days, the accumulation ratio on Day 3 (AUC 0-24 , day 3/AUC 0-24 , day 1) was in the range of 1.5-2.0 in the studied dose range (10-150 mg) and consistent with an elimination half-life of around 24 hours. Urine analysis for unchanged KAE609 revealed negligible amounts (≤0.01%) excreted renally. The high fat food intake with 30 mg single dose did not aff ect the extent of KAE609 absorption however C max was reduced by around 27% and increased T max (from 2.5 to 4 hours). KAE609 was generally well tolerated within this study, with transient gastrointestinal and genitourinary adverse events of mild to moderate intensity, which increased with rising doses. Conclusions KAE609 is a new antimalarial with potential to address artemisinin resistance, and demonstrates a half-life of around 24 hours and dose-proportional increase in systemic exposure. KAE609 was generally well tolerated within this study, with mild to moderate intensity gastrointestinal and genitourinary adverse events reported with increasing dose. There were no study fi ndings that would preclude dosing in malaria patients and a human malaria patient trial, which immediately followed this study, showed that KAE609 clears parasitemia rapidly in falciparum and vivax malaria patients. The K13 gene mutations have been found to be associated with artemisin resistance in Cambodia, although the relevance of these mutations on artemisinin resistance in other endemic areas have to be better documented. We present here new data on K13 mutations and on the artemisinin resistance outside Cambodia. We propose to open the discussion about how these new fi ndings have to be interpreted regarding the emergence and spread of artemisinin resistance and their usefulness to identify and prevent the spread of resistant strains in order to reach the malaria control and elimination global program goal. 
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Background
The occurrence of multiple, genetically diff erent, parasites in P. vivax -infected patients is well known but often conveniently disregarded. This complexity of infection has long been diffi cult to study due to a lack of molecular markers. Genome sequencing approaches could circumvent this limitation but require tailored analyses that have not always been implemented.
Materials and methods
Here, we analyze genome sequence data generated by us and others from P. vivax fi eld isolates and monkeyadapted strains to characterize, across the entire genome, SNPs and sequence rearrangements. We also genotyped several blood samples infected by the same monkey-adapted strain to better understand the changes happening during the generation of these strains. Results All fi eld isolates sequenced so far show evidence of complex infections, with typically 2-4 strains present at >5%. We show that it is possible, empirically and analytically, to rigorously diff erentiate these parasites and reconstruct haploid genome sequences from these complex infections. Our analyses also demonstrate that the presence of distinct parasites in the original patient infection can lead to genetic heterogeneity in monkey-adapted strains. Conclusions Our fi ndings reveal the pervasiveness of complex infections in P. vivax and show that erroneous genetic conclusions can be made if this aspect of the parasite's biology is not carefully addressed. We show that diff erent approaches enable to rigorously assess complexity of infection and to separate strains within an infection. In addition to their relevance for genetic and genomic studies, our fi ndings have important implications for in vitro and ex vivo studies of P. vivax and provide a framework to better design and control such functional studies. the challenges in malaria research is to fi nd the correct methods to eradicate current strains while avoiding the appearance of new resistant strains. To recommend methods for malaria control, it is necessary to understand disease transmission and parasite dynamics and take into consideration spatial, temporal and environmental variations. In order to describe these elements, mathematical, stochastic and computational models have been developed. In this work, an agent-based model represents malaria transmission, in which the defi ned agents are humans and mosquitoes. The interaction between these two agents is simulated in a spatial setting considering environmental and temporal variations. In particular, the parasite is modeled as a characteristic of both agents, considering mutation and recombination and their eff ects on drug resistance emergence. On one hand, the model recreates the gonotrophic cycle of mosquito (Anopheles gambiae) and includes population births and deaths. It also represents the mosquito's epidemiological states: susceptible, exposed and infected (SEI). On the other hand, the model includes a human population in which sulfadoxine-pyrimethamine is applied as an antimalarial drug with 100% coverage. Human dynamics also includes births, deaths and migration. Additionally, the represented human epidemiological states in the model are SEIS, in which the reinfection probability depends on the disease exposure history. The interaction between both mosquitoes and humans occurs in a simulated scenario of one square kilometer including environmental conditions that aff ect the mosquito life cycle. The parasite life cycle is modeled during the interaction between mosquitoes and humans. Due to selection pressure as a consequence of sulfadoxine-pyrimethamine use, strains with fi xed resistant mutations at the DHFR and DHPS loci emerge. This is modeled through the emergence of fi fteen drug-resistant mutations and the subsequent recombination among alleles, generating mutational pathways developing into more resistant strains. Moreover, super-infection in humans (two genotypes) and mosquitoes (two genotypes -infection and the result of recombination) is represented. Simulations for high transmission parameters are consistent with the literature, presenting coherent times for each strain appearance, and showing a mutational pathway under high transmission settings and 100% of drug coverage. Thus, measuring the prevalence of each genotype in the model allows the analysis of diff erent cases to eradicate the disease by the correct usage of control strategies. Furthermore, the model is being adapted for representing low transmission scenarios. 
Anopheles larvae were collected from six localities each in Lagos and Oyo State. These were reared to adults and 3-5 day old adults were exposed to 4% DDT according to the standard WHO protocol. Resistance profi les were compared between Lagos and Oyo State samples using a standard t-test. All Anopheles mosquitoes exposed were identifi ed to species using external morphology followed by PCR assay and restriction enzyme digest. Underlying genetic diff erentiation was fi rst determined by conducting 2La inversion PCR on 231 Anopheles gambiae s.s. DDT resistant samples selected randomly from all localities. Inversion karyotype data was compared between groups (Lagos and Oyo State) using standard F ST estimates. Genetic diff erentiation was further scrutinized by assessing the assortment of 10 microsatellites by PCR using the DNA products from the inversion analysis. Microsatellite data were analyzed with one locus estimates following standard ANOVA. Results Anopheles mosquitoes were resistant to DDT in all the localities surveyed with signifi cant variation in mortality (at P < 0.05) between the two groups. All Anopheles from Lagos and Oyo State used for the study were morphologically identifi ed as Anopheles gambiae s.l. PCR assay identifi ed all Lagos samples as An. gambiae s.s. and An. coluzzii while An. gambiae s.s. and An. arabiensis constitute the Oyo State population with sympatric occurrence of An. coluzzii and An. gambiae The resistance profi le showed the same trend with chromosomal inversion 2La profi le. The F ST for inversion 2La was 0.09 and 0.07 for Lagos and Oyo State respectively (P > 0.05). Microsatellite locus estimate revealed that four loci (AG2H26, AG2H637, AG2H772 and AG2H603) located within and outside inversion 2La accounted for the bulk of genetic diff erentiation between populations. Conclusions These data suggest that inversion 2La and four microsatellite loci are associated with the development of resistance to DDT in Anopheles gambiae s.s. populations from Lagos and Oyo States in South West Nigeria. Microsatellite analysis shows that gene fl ow is extensive across all loci and that assortment of the four loci located within or close to inversion 2La suggests that the primary factor controlling DDT resistance is likely within or close to inversion 2La. A candidate gene that may at least partially account for these data is the kdr locus which is located near the centromere of arm 2L.
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The clinical burden of microscopically patent and sub-microscopic P. falciparum and P. vivax malaria in pregnancy in Indonesia Rukhsana Ahmed Background Malaria in pregnancy poses a major public health problem in Indonesia with an estimated 6 million pregnancies at risk of P. falciparum or P. vivax malaria annually. The association between microscopically patent and PCR positive sub-microscopic malaria with maternal anaemia and low birth weight babies was assessed in Southwest Sumba and Jayapura district, Papua, Indonesia. Materials and methods Cross sectional surveys were conducted between June 2008-May 2009 in antenatal women and at delivery including home deliveries in SW Sumba (low-moderate transmission) and Jayapura (high transmission). Maternal and placental blood samples were obtained at antenatal attendance and at delivery for haemoglobin measurement, smear microscopy and PCR. Results A total of 4230 women (2598 attending antenatal care and 1632 at delivery) were enrolled. The prevalence of maternal parasitaemia detected by microscopy was 7.0% [(180/2598) (mono-infection with P. falciparum: 58.3%, with P. vivax: 20.6% and 0.5% P. ovale and 5.6% mixed infections (P. falciparum + P. vivax), and this was 12.3% by PCR (P. falciparum 58.4%, P. vivax 31.5%, mixed (P. falciparum + P. vivax): 10.1%) and 10.7% in Sumba and 14.2% in Jayapura, respectively. Submicroscopic parasitaemia (microscopy negative, PCR positive) was detected in 8.3% women. With patent infections only P. falciparum was associated with moderate-severe anaemia (Hb ≤9 g/dL); [RR 2.2 (95% CI 1.7-2.9) P. vivax RR 0.5 (0.3-0.9)] whereas with sub-microscopic infections both species were associated with increased risk of moderate to severe anaemia [P. falciparum: RR 2.1 (95% CI 1.6-2.8) and P. vivax: RR 1.9 (95% CI 1.3-2.7)]. The prevalence of placental malaria was 4.8% (72/1632) by PCR and 3.3% sub-microscopically; this was 2.4% in primigravidae, 3.1% in secundi and 1.7% in multigravidae (≥3 pregnancies). The mean diff erence in birth weight in women with patent placental P. falciparum infection compared with uninfected women was 101 g (95% CI 70-273 g) with RR 2.1 (95% CI 1.2-3.0) for low birth weight. The reduction in birth weight with sub-microscopic infection was 70 g (63-204 g) with low birth weight RR 1.7 (95% CI 1.0-2.5). Corresponding fi gures for P. vivax were: patent placental infections: 252 g (57-560 g), low birth weight RR 4.7 (95% CI 2.2-67); and for sub-microscopic infections the mean diff erence in birth weight was 146 (70-364 g); low birth weight RR 2.9 (95% CI 1.6-3.4). Conclusions Sub-microscopic infections are common in eastern Indonesia and are associated with maternal anaemia and marked reductions in birth weight. Strategies that prevent sub-microscopic infections such as intermittent preventing therapy or that which results in their early detection and treatment, such as intermittent screening strategies should now be explored in South-east Asia.
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Malnutrition infl uences tumor necrotic factor-alpha (TNF-α) response among Plasmodium falciparum (Pf) malaria patients in Nigeria Olusola Ajibaye 1,2 , Akiniyi Osuntoki
Methods Volunteers (1,838) with a history of fever or axilliary temperature ≥37°C were screened microscopically for Pf in a crosssectional study at Ijede General Hospital, Lagos, Nigeria. Body mass index (BMI) of patients was determined and used as a measure of nutritional status. A BMI of <18.5 kg/m 2 was taken as an index of malnutrition while participants <20 years were further classifi ed based on Z-scores (Z-Scores ≤-2) into stunted, wasted or underweight. TNF-α, interleukin-1β and interleukin-12 were determined by ELISA and haematological parameters (Full blood count) were measured using Beckman Coulter Closed Tube Automated Hematology System. Statistical analysis was done using SPSS Version 17. The study protocol was approved by NIMR Institutional Review Board. Results A total of 364 patients comprising of 47% males and 53% females with a median age of 10 years were recruited for which average BMI was 18.19+6.10. Malaria prevalence was 20.85% and malnutrition rate 62.5%. In the <20 years group, 24 (16.7%) were stunted, 30 (20.8%) were underweight and 48 (33.3%) were wasted. TNF-α was associated with age, observed to be higher in <5 years (P = 0.001). Mean levels of TNF-α were signifi cantly higher in malnourished patients P < 0.05. Conclusions This study suggests that nutritional status modulates malaria outcomes and pattern of progression in all ages with an inference of high malnutrition rate in the studied population. Plasmodium vivax is the most widely distributed human malaria parasite in the world and despite nearly 2.5 billion people living at risk, only four vaccines have been assessed in phase I clinical trials and only one has progressed to a phase II trial showing no sterile effi cacy. We started to develop new challenge models to assess the effi cacy of several new P. vivax pre-erythrocytic vaccine candidates (PVX_091700; PVX_121950; PVX_084090; PVX_099035; PVX_095375; PVX_000975; PVX_003665; PVX_000810) in mice. Our model is based on creating mutant P. berghei (rodent malaria) lines expressing P. vivax antigens through a new method called "Gene Insertion/Marker out" (GIMO). In addition, we are cloning the P. vivax pre-erythrocytic vaccine candidates in recombinant chimpanzee adenovirus (ChAd) and modifi ed vaccine Ankara (MVA) vectors. Upon generation of transgenic parasites and recombinant viruses, a faster assessment to determinate the effi cacy of all new P. vivax vaccine candidates can be achieved by using prime/boost immunization regimens followed by a challenge with corresponding transgenic chimera parasites. Background Health Management Information Systems (HMIS) are a crucial tool for supporting planning and decision-making. The benefi ts of such systems will depend on the quality of the data they provide and on the response capacity of the decision-makers [1] . The analysis of malaria incidence records of the HMIS, in Uganda, faces two main complications. First, artifi cial trends induced by a non-negligible and variable rate of non-reporting hospitals. Second, lack of comparability across time, due to changes in the districts boundaries. Materials and methods We propose a method for estimating the incidence of malaria for the diff erent district defi nitions across time. Although we have information for the whole country across many years, this task requires making estimates for periods where data is not available for a specifi c district delimitation. We provide disease maps based on HMIS information by exploiting the relationship with its environmental drivers. Our approach relies on the Gaussian process framework. In particular, we use multiple output kernel techniques [2] to achieve consistency between the totals and subtotals of incidence records at diff erent levels of territory aggregations. In the case of map generation, this approach allows us to combine information from diff erent sources at diff erent spatial resolution. We use the HMIS malaria records from 2003 to 2013. The records consist of weekly information aggregated within districts. The information available also includes the number of hospitals reporting each week. We use the normalized diff erence vegetation index and land surface temperature measurements, both commonly used for identifying suitable habitats for mosquito breeding [3] . Results For recently created districts, our method allows comparability between the current malaria incidence and periods before they started reporting to the HMIS. The probabilistic model defi ned allows HMIS users to generate samples from a incidence distribution to develop further analysis. We also generate disease maps by combining administrative records with remote sensing data. Background Pediatric artemisinin-based combination therapy formulations have the potential to improve the eff ectiveness and accuracy of dosing in young children. Coartem® (artemether-lumefantrine; AL) Dispersible was developed and launched in partnership with the Medicines for Malaria Venture for the treatment of uncomplicated Plasmodium falciparum malaria and is the fi rst pediatric antimalarial to receive Swissmedic approval and meet WHO specifi cations for use in infants and children ≥5 kg. Materials and methods PubMed, Ovid and clinical trial registry databases were explored for publications on AL dispersible formulation in children with acute uncomplicated P. falciparum malaria, and 11 publications (6 original and 5 review articles) involving 674 infants and children were identifi ed. Results In a palatability study, sweet tasting cherry was the preferred fl avor by children for AL dispersible. Pharmacokinetic profi le of AL dispersible was comparable to AL crushed tablets. Effi cacy and safety of dispersible formulation versus crushed tablet was evaluated in a large, randomized, multicenter study in 5 sub-Saharan African countries. Effi cacy and acceptability of AL dispersible were also compared to dihydroartemisinin-piperaquine (DP) pediatric in another open-label, randomized study in Kenya. A total of 674 children were randomized in both studies to receive AL dispersible with a mean age of 38.5 months, body temperature of 38.1°C and parasite density 41,974/μl.
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Malaria Journal 2014, Volume 13 Suppl 1 http://www.malariajournal.com/supplements/13/S1 PCR-corrected cure rate was 97.8% at day 28 and 96.4% at day 42; similar to AL crushed tablets and DP in respective studies. PCR-corrected cure rate at day 28 was not related to food intake, although consumption of milk/low fat meal increased lumefantrine bioavailability compared to no food. Effi cacy of AL dispersible was comparable in children with diff erent body weights. Median parasite and fever clearance times were 34.3 and 7.9 hours, respectively. The safety profi le of AL dispersible was similar to that of crushed tablets. Acceptability of AL dispersible was signifi cantly better than DP pediatric (ease of use: P = 0.007; taste of medicine: P = 0.001). Conclusions AL dispersible was specifi cally tailored for the pediatric population and off ers a convenient formulation with effi cacy and safety similar to that of standard crushed AL tablets. Background Reducing human infectivity of malaria parasite through early and eff ective treatment amongst under-fi ve children is a major concern of WHO & MDGs 4 & 6. Getting mothers to bring their children to the nearest facility early for malaria treatment remains a major challenge. Aim To explore health seeking behaviours and cultural attitudes of mothers of under fi ve children suff ering from malaria in Ile Ife using moderate interviews and providing recommendation to the Ministry of Health of Osun State to serve as knowledge basis for developing appropriate intervention.
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Materials and methods
The study employs a qualitative research with the aid of purposive sampling, 16 women who brought their under fi ve children to hospital for malaria treatment were recruited. A moderate interview was used to explore the experiences of the mothers and the data generated was subjected to thematic content analysis. Results Five themes emerged from the study. All respondents recognized fever as the major feature of malaria but their knowledge of what causes it, symptoms and sign was poor. They all perceived malaria as a simple disease for which mothers should be comfortable to apply home based remedies such as herbal concoctions. Religious beliefs did not prevent mothers from seeking hospital care but some are aware of mothers that rely on Holy water and prayer to treat malaria. Poverty is seen as an impediment to seeking treatment mostly by women in a polygamous relationship. Fear of use of injection to treat malaria in hospital coupled with perceived poor attitude of hospital staff was considered by some mothers. Conclusion The study observed that mothers had poor knowledge of malaria; cultural beliefs in home remedies and poverty are issues that aff ect malaria outcome. Health education of the malaria life cycle, treatment and prevention is necessary for mothers as well as empowerment of women. Background Prompt treatment of malaria following adequate diagnosis helps to reduce morbidity and mortality in children. Lack of resources and adequate manpower in developing countries make malaria microscopy diffi cult. The Rapid Diagnostic Test kit (RDT) remains unpopular despite its availability and ease of use because of lack of local research on its eff ectiveness leading to over-prescription of Artemisinin Combination Therapy (ACT).
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Reliability of Rapid Diagnostic Tests in the diagnosis of malaria amongst children in two communities in South West
Materials and methods A total of 132 children age range 1-9 years were screened for malaria routinely with rapid diagnostic test kits (RDTs HRP 2) and malaria microscopy at the general outpatient department of OAU Teaching Hospital as well as at a comprehensive health centre at Imesi Ile, South West Nigeria while marking the 2013 World Malaria Day. Needle prick was used to collect blood sample for thick and thin smear. Giemsa stain was used to prepare the slide for microscopic examination. Results A total of 132 children were recruited into the study. There were more females (59.1%) than males (40.9%). 35 (26.5%) children tested positive while 97 (73.5%) children tested negative for Plasmodium falciparum. In the Microscopy category, 35 (26.5%) children tested positive while 97 (73.5%) tested negative for malaria parasite. Out of the 35 children tested positive, RDT picked 33 as positive and 2 as negative, (sensitivity = 94.3%). While out of the 97 that tested negative for microscopy, RDT picked 94 as negative and 3 as positive (specifi city = 96.9%). The positive predictive value and negative predictive values are 91.7% and 97.9% respectively. Conclusions Rapid Diagnostic Test is an eff ective diagnostic tool for malaria amongst children in the study population. Primary and secondary health centres in the region should adopt Rapid Diagnostic Test in malaria diagnosis before administration of ACTs to avoid unnecessary treatment. It is hypothesised that intraerythrocytic malaria parasite metabolism is not just fulfi lling the need for ATP generation, but is highly evolved to support rapid proliferation, similar to what is seen in other rapidly proliferating cells such as cancer cells. Evidence is presented that deregulated glycolytic activity coupled with impaired mitochondrial metabolism is a metabolic strategy to generate glycolytic intermediates essential for rapid biomass generation for schizogony. The role of the parasite mitochondrion during key stages of the parasite life cycle makes it an attractive target for the development of novel prophylaxis, treatment and transmission blocking drugs. Using a targeted pharmacometabolomic approach, additional mitochondrial targets with therapeutic potential are identifi ed and the potential of the development of inhibitors against these novel targets is discussed in the context of recent experiences with bc 1 and dihydroorotate dehydrogenase-targeting drug development programmes and within the context of current target product profi les for the malaria elimination agenda.
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Controlled human malaria infections using aseptic, purifi ed cryopreserved Plasmodium falciparum sporozoites administered by needle and syringe Peter Billingsley stephensi mosquitoes to bite human subjects. This approach has proven highly successful for studies of drugs and vaccines. However, its use has been limited to the few clinical centers, which have access to Pf-infected mosquitoes. Sanaria Inc. has established a new CHMI methodology whereby aseptic, purifi ed, cryopreserved, infectious sporozoites (SPZ) of Pf are used to infect volunteers when administered by needle and syringe. This product is known as PfSPZ Challenge. Here we summarize the results of seven clinical trials in the Netherlands, UK, Tanzania, USA, Germany, Spain, and Kenya including 178 subjects. Four of the trials were done in countries where CHMI had never been done before. These trials assessed intradermal, intramuscular and intravenous administration of varying doses of PfSPZ Challenge. The three primary goals of 100% infection rates, a prepatent period comparable to the bite of fi ve Pf-infected mosquitoes (11 to 11.5 days) and a dose response have been met by intravenous and intramuscular administration. PfSPZ Challenge opens up the potential for CHMI to be done in any research facility set up for clinical malaria studies (see presentation by Sheehy et al.), including sites to which transport of A. stephensi is diffi cult or impossible (i.e. any site in Africa). The results of all the studies will be presented. As per the 2007 Global Malaria Eradication Plan, malaria transmission blocking is seen as key to malaria elimination strategies. A highlight that has emerged from gametocytocidal assays to identify novel compounds with malaria transmission blocking ability is that, unlike asexual-based assays, greater variability in end-point readout may exist between these assays that interrogate diff erent parasite biological functions. Drug mode-of-action is likely to be an important factor on this outcome. Such variability may be mitigated by screening compounds based on similar pharmacophores in series. One of the major concerns with the current assay platforms is their inability to be robustly used to screen variant pharmacophores accurately as the diff erent assay principles may interrogate diff erent biological functions. As such, compounds targeting a specifi c biological pathway may in extreme cases either fail in a certain assay, or by contrast, may be fl agged as false positives. Taking assay platform diff erences into account, and relying on good intra-assay variability for each assay optimized in our laboratories, the ATP, pLDH, luciferase reporter and PrestoBlue™ assays were compared in context of a blinded MMV 10-compound set. All the assays were performed in parallel on the same gametocyte population (except for the luciferase reporter lines). The remaining parameters for each assay were all comparable. In each case, the assay was performed for 48 h of continuous drug pressure for at least three replicates. Although direct comparison of absolute inhibition values are diffi cult between assay platforms, similar trends were observed including comparative performance of the luciferase marker assay and the PrestoBlue™ assay for e.g. DHA and Methylene blue. Interestingly, the ATP assay could not detect any inhibitory activity for some quinoline family members and may therefore be more sensitive in indicating the inability of these compounds to inhibit gametocytes. Data from the luciferase reporter assays for these compounds indicate that the compounds are indeed more active against early stage gametocytes. The signal obtained for these compounds in the PrestoBlue™ and pLDH assays may therefore rather refl ect the inability of these assays in discriminating activity of compounds against earlier stages of gametocytes, whereas the ATP assay more accurately refl ect these compounds' activity. Whilst this data is informative from a biological perspective and may provide indications of the drug mode of action, it does highlight the care that has to be taken in screening platforms where compounds may be falsely assigned activity (or lack thereof ) based on a single assay. Background Vaccination against liver stage malaria antigens can induce T cell-mediated immunity to the disease [1] . A viral vector vaccination regime undergoing Phase 2b clinical testing uses chimpanzee adenovirus 63 (ChAd63) and Modifi ed Vaccinia virus Ankara (MVA) encoding liver stage antigen Thrombospondin-Related Adhesion Protein (TRAP) fused to a malaria multi-epitope string (ME). This regime induces high frequencies of antigen-specifi c T cells, providing 21% sterile protection and a delay to patent parasitaemia in a further 36% of vaccinees, following controlled human Plasmodium falciparum malaria infection (CHMI). Monofunctional IFNg-producing CD8 + T cells correlate with vaccine-induced protection but the associated protective mechanisms remain unidentifi ed [2] . Developing standardized immunological and functional assays is a researchspecifi c aim of the WHO's Malaria Vaccine Technology Roadmap, with emphasis on novel immunoassays for investigation of cellular products refl ecting cell-mediated malaria immunity [3] . Development of an in vitro parasite killing assay is underway, which quantifi es cell-mediated killing of Plasmodium-infected human hepatocytes and investigates the underlying functional mechanisms. Additionally, the assay aims to compliment in vivo CHMI studies. Materials and methods Human hepatoma cell lines were infected with transgenic P. berghei sporozoites expressing TRAP from P. falciparum. Freshly separated peripheral blood mononuclear cells from partial-HLA class I matched ChAd63.MVA ME-TRAP human vaccinees were enriched for CD8 + T cell populations. Following hepatocyte infection, enriched CD8 + T cells were added and incubated overnight. Level of infectivity was measured by fl ow cytometry through expression of GFP under a P. berghei promotor. TRAP-specifi c killing was calculated by subtraction of non-specifi c killing in wild type P.berghei-infected hepatocytes. Results Transgenic P. berghei sporozoites with full replacement of wild type TRAP infect human hepatoma cells at >1% frequency. Preliminary results measure a 9.5-22% TRAP-specifi c reduction of infected hepatocytes after addition of CD8 + T cells from ChAd63.MVA ME-TRAP vaccinees. Equivalently, TRAP-specifi c parasite killing was not detected following addition of CD8 + T cells from control volunteers. Conclusions Successful use of transgenic parasites and the preliminary results obtained provide proof of assay concept for this in vitro system. Further optimization will permit the investigation of cell-mediated parasite killing of CD8 + T cells from a larger number of vaccinees and extend to exploration of vaccine-induced mechanisms of protection.
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High frequency of submicroscopic gametocyte carriage after the treatment of uncomplicated malaria with ACTs Marielle Karine Bouyou-Akotet more common in patients with asexual forms, and the occurrence of recrudescence or reinfection in patients could also be favored and contribute to the maintenance of a large reservoir of parasites. The aim of this study was to determine the prevalence of submicroscopic gametocytaemia in patients treated for uncomplicated malaria. Materials and methods Gametocytes carriage and density were estimated by Pfs25mRNA amplifi cation using QT-NASBA in samples obtained at enrolment and during the follow-up (day 21 to day 42 posttreatment) of children treated with either artesunate-amodiaquine (ASAQ) or artemether-lumefantrine (AL). Data were analyzed according to the study visit, the presence of asexual parasites, the type of treatment and the treatment response. Results Samples from 48 children were analyzed; 23 were treated with ASAQ and 25 with AL. They had 147 visits, all corresponding to treatment failure with either ASAQ or AL. None of the patients had a microscopic gametocytaemia. Overall, the frequency of SMG carriage was 51%, comparable at day 0 between the ASAQ (53%) and the AL (56%) patients (P = 0.6). During the post-treatment visits, it was 58% and 44% in the ASAQ and in the AL groups respectively (P = 0.4). When paired samples of 23 children were analyzed, the gametocytaemia was positively correlated with the asexual form density the day of treatment failure (rho = 0.4 in the ASAQ group and rho = 0.5 in the AL). Logistic regression analysis showed that recrudescent infection (aOR: 12.9 [1.1-14.9]) were independent risk factors for SMG carriage whereas no association was found with the type of treatment, age and number of episodes. Conclusions The frequency of SMG carriage is high after ACT treatment whatever the combination used. A strong association between the presence of gametocytes and a recurrent infection is also observed. [1] induces protection which has been associated with high titres of antibodies against sporozoites. Effi cacy against clinical malaria in infants of 5-17 months and 6-12 weeks was 55.8% and 31.3% respectively. A successful malaria vaccine will likely need to induce both cellular and humoral immunity in order to achieve a deployable level of effi cacy in the target age groups. Prime-boost immunisation with viral vectors ChAd63 and MVA, both encoding ME-TRAP, has been shown to induce high T cell responses and modest antibody responses to the pre-erythrocytic malaria antigen TRAP. A Phase II study with this vaccine regime in malaria-naïve adults showed signifi cant effi cacy, which correlated with frequency of monofunctional CD8+ T cells secreting IFNγ. TRAP antibody titres were modest and did not correlate with protection [2] . In contrast to this, high titres of vaccine-induced anti-TRAP antibodies are measured in infants in malaria-endemic settings. Materials and methods Antibody titres were measured in 138 malariaexposed children vaccinated with ChAd63 MVA ME-TRAP in three Phase I studies in The Gambia and Burkina Faso. Age groups at fi rst immunisation were 2-6 years, 5-12 months and 10 weeks in The Gambia and 5-17 months in Burkina Faso. Avidity and isotype profi les were also analyzed. Results Antibody responses to TRAP were signifi cantly higher in 10 week old and 5-12 month old infants in The Gambia and 5-17 month old infants in Burkina Faso compared to 2-6 year old children and adults in The Gambia and malaria-naïve UK adults. IgG isotype responses were predominantly IgG1 and IgG3 and we also detected IgA and IgM. TRAPspecifi c IgG avidity was signifi cantly higher in Burkinabe infants aged 5-17 months and Gambian infants aged 5-12 months compared to Gambian adults and 2-6 year old children. TRAP-specifi c IgG1 avidity signifi cantly correlated with age at vaccination in 5-17 month old Burkinabe infants and was signifi cantly higher than in 10 week old Gambian infants. Functional activity of anti-TRAP antibodies will be analysed in vitro using a sporozoite invasion inhibition assay. Conclusions We demonstrate excellent humoral immunogenicity in key target populations vaccinated with a pre-erythrocytic malaria vaccination regime, exceeding that seen in UK malaria-naïve adults. References Anemia is a typical manifestation of Plasmodium vivax infection and one of the leading causes of morbidity and mortality, particularly in pregnant women and children less than fi ve years old. Despite the magnitude of the problem, there remain major unsolved questions about its etiology. In this context, we have addressed the following question: Are antibodies directed to erythrocyte membrane proteins involved in the accelerated clearance of red blood cells (RBCs) by phagocytes leading to anemia during P. vivax infection? We performed immunoproteomic assays trying to characterize proteins that are targets of antibodies. Sera from four groups of subjects were tested against a non-infected O+ erythrocyte membrane extract and are included in our study: P. vivax anemic individuals (PvAN); P. vivax nonanemic individuals (PvNA); non-infected individuals with anemia by other etiologies (NIAN); and non-infected and non-anemic individuals (NINA). Immunoblots revealed a diff erential pattern of RBC protein recognition related to the four studied groups. The breadth and the magnitude of antibody responses against RBC membrane antigens were higher in NAPv and ANPv, corroborating our previous results obtained by ELISA and 1-D immunoblot. Now, these proteins are being identifi ed by peptide mass fi ngerprint. Next, we will confi rm their identity by MALDI TOF/MS-MS, validate and categorize them in relation to location, family and function. Highly immunogenic and diff erentially recognized proteins will represent potential candidates for diagnostic or prognostic biomarkers of anemia in P. vivax infections. Moreover, data generated here will contribute to the better understanding of mechanisms enrolled in vivax anemia pathogenesis. We report here our investigations on plants belonging to the botanical genus Aspidosperma (Apocynaceae) that are used to treat malaria and/or fevers in Brazil, aiming to prepare standardized alkaloid extracts for phytomedicines development. Ethanol and alkaloid extracts of A. parvifolium and A. subincanum barks were prepared and their in vitro antiplasmodial activity was evaluated against Plasmodium falciparum (W2 strain) by the pLDH method. Bioguided fractionation of the active alkaloid extracts was undertaken. A study on antiplasmodial activity versus alkaloids content variation from three A. subincanum specimens that were collected in diff erent regions was carried on by HPLC-UV. Ethanol and alkaloid extracts from A. parvifolium and A. subincanum were evaluated in toxicological studies in male and female Swiss mice and male Wistar rats (n = 10); a control group was included in the experiments. At the end of treatment, animals were sacrifi ced, hematology and serum biochemical analyses were performed. Fractionation of alkaloid extracts from A. parvifolium and A. subincanum guided by in vitro assays against P. falciparum (W2 strain) led to the isolation of the indole alkaloids uleine (Oliveira et al., 2010) and N-demethyluleine. HPLC-UV and LC-UV-MS/ESI analyses of the extracts disclosed uleine as the major constituent, its content reaching 70.7% in the alkaloid extract from A. subincanum (ASALB) which was more potent than uleine and N-demethyluleine themselves in the in vitro assays, as can be inferred from the selectivity indexes in relation to HepG2 cells (SI = CC 50 /IC 50 ) of ASALB (100), uleine (44) and N-demethyluleine (21). Moreover, a signifi cative variation on the contents of these two alkaloids was observed for the same plant species when collected in diff erent regions (Paula, 2014). Both ethanol and alkaloid extracts from A. parvifolium bark were relatively safe, producing minor changes in the parameters evaluated, especially in smaller doses, thus making feasible their future use in phase I clinical trials. On the other hand, high toxicity of both extracts from A. subincanum bark was observed in doses >200 mg/kg. The present results point to the necessity of rigorous investigation of traditional antimalarial plants including in vitro studies for identifi cation of active natural products, standardization of extracts to be submitted to pre-clinical toxicological studies and controlled clinical trials. Our results disclose that effi cient and safe phytomedicines might be developed from standardized crude or semi-purifi ed extracts of Aspidosperma species containing the active chemical entities. Background Five artemisinin combination therapies (ACTs) are currently recommended for treatment of uncomplicated malaria in Africa. Whilst the artemisinin component has a short half-life, the partner drugs give rise to diff ering durations of post-treatment prophylaxis, protecting from re-infection and reducing transmission. We compared the duration of post-treatment prophylaxis of artemether-lumefantrine (AL), dihydroartemisinin-piperaquine (DHA-PPQ) and artemisinineamodiaquine (AS-AQ). Materials and methods We pooled the results from analyses of 6 trials (1651 individuals) of AL versus DHA-PPQ and from 18 trials (5060 individuals) of AL versus AS-AQ. The time to re-infection after treatment was used to estimate the duration of post-treatment protection accounting for the variation in transmission intensity between settings. This duration was then used in a mathematical model of malaria transmission to estimate the comparative public health impact of each drug used for 1st-line treatment in low, medium and high transmission settings. Results We estimated a mean duration of post-treatment protection of 10.7 days (95% CI: 10.2-11.2) and 13.8 days (95% CI: 10.2-22.8) for AL from the two analyses, 29.4 days (95% CI: 16.4-48.8) for DHA-PPQ, and 11.8 days (95% CI: 11.0-12.5) for ASAQ. There was no substantial diff erence in the public health impact of using AL versus AS-AQ. Use of DHA-PPQ for 1st-line treatment averted 8.3 additional cases per 1,000 people (0.8% of all cases) over 5 years compared to AL or AS-AQ. This protective eff ect was stronger in areas of high transmission as well as in seasonal settings. Conclusions While it is important to maintain a diverse set of fi rst-line treatments for uncomplicated malaria, our results suggest that partner drugs with a longer half-life could be benefi cial in reducing repeat episodes and onward transmission, particularly in high and seasonal transmission areas.
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Challenges in optimizing the histidine rich protein 2-detecting rapid diagnostic test Robert Burton, Kathy Tietje, Kelly Ebels, Paul LaBarre PATH, Seattle, WA, USA Malaria Journal 2014, 13(Suppl 1):P20
Malaria programs aimed at eliminating Plasmodium falciparum (Pf ) incorporate active infection detection strategies to target the subclinical transmission reservoir. Currently available immunochromatographic lateral fl ow tests lack the sensitivity required for Pf malaria elimination; the limit of detection (LOD) of these rapid diagnostic tests (RDTs) is above that which is required to identify all transmissible infections. Malaria RDTs with a signifi cantly improved LOD would enable more eff ective elimination interventions while retaining the critical advantages of low cost, ease of use, and rural deployment capability. Histidine-rich protein 2 (HRP2) is a high-priority target analyte for identifying individuals at risk of transmitting Pf. HRP2 protein is secreted by Pf parasites in relatively high concentrations, is widely conserved among Pf strains, and persists in human plasma for up to four weeks. These characteristics allow HRP2 antigen detection even in the absence of circulating parasites during cyclical sequestration. However, the highly polymorphic nature of HRP2 makes optimization of RDTs challenging. Current HRP2-detecting RDT reagents primarily target Type 2 (AHHAHHAAD) and Type 7 (AHHAAD) HRP2 motifs, and independent antibody discovery confi rms the most common selection of a C1-13/PTL-3 antibody conjugate pair yields the best RDT performance for the majority of parasite strains. In scenarios where malaria transmission rapidly decreases, exclusive use of a diagnostic whose sensitivity varies with the number of HRP2 epitope repeats can result in single axis evolutionary pressure, increasing selection for lessdetectable parasite strains. To evaluate the feasibility of developing an HRP2-based RDT that is highly eff ective in mass testing and treatment programs, we have assessed the technical characteristics of HRP2 reagents. Our aim is to facilitate the development of improved malaria HRP2 RDTs by: (1) incorporating an understanding of HRP2 structure-function relationships and their impact on epitope-antibody interactions and adaptation, (2) correlating HRP2 concentration levels (in pg/mL) with traditional malaria diagnostic metrics (parasites/mL) for comparative evaluation of tests, and (3) predicting optimal capture reagents to improve and sustain HRP2 RDT performance. Based on our ongoing analysis, we present a product development strategy that combines capture reagent and platform innovations that can be used to make highly sensitive Pf malaria RDTs. In addition, we present criteria for the rational selection of HRP2 protein and parasite culture controls to support the product lifecycle from development through commercialization and scale-up. As the only marketed drug that is capable of clearing mature P. falciparum gametocytes, primaquine off ers a unique ability to stop malaria transmission from humans to mosquitoes. Despite its potential role in malaria control and elimination, the widespread adoption of primaquine has been slow due to its ability to induce hemolysis in G6PD-defi cient individuals. While hemolysis is understood to be dose dependent, there are limited data to support the safety and effi cacy of current WHO recommendation to give, in conjunction with an artemisinin-based combination therapy, single low-dose primaquine (0.25 mg/kg) to all parasitologically-confi rmed P. falciparum cases in areas threatened by artemisinin resistance or in settings approaching elimination. In March 2012, a group of experts from academia, industry, nongovernmental organizations, malaria programs, and funders convened to discuss existing data on the use of primaquine as a malaria transmission blocker. The meeting served to identify roadblocks and to propose a roadmap to establish whether low-dose primaquine can be safely and eff ectively deployed to block P. falciparum malaria transmission in sub-Saharan Africa [1] . Since then, much knowledge has been gained on the pharmacokinetics, safety and effi cacy of low-dose primaquine. Regulatory barriers to the supply and manufacture of low-dose primaquine in Africa have also been investigated. In March 2014, the group of experts reconvened to discuss roadmap progress and update potential knowledge gaps that need to be addressed in order to determine if and how low-dose primaquine can be implemented as a malaria transmission blocker. We will provide roadmap updates based on the latest meeting and will highlight gaps to welcome discussion and advice from the malaria research community. Reference Background One of the constraints in the development of antimalarial vaccines is the limited availability of experimental models that reliably reproduce the infection and the immunopathology observed in human malaria. The best experimental models are Saimiri and Aotus neotropical primates, but they have as important limitations, the need for splenectomy for the expression of high and consistent parasitemias. The clodronate-liposome (CL) has been used to deplete macrophages in several experimental models and we tested the hypothesis that their use in Saimiri would allow the development of consistent P. falciparum parasitemias without the need for splenectomy. Methods Two studies with non-splenectomized animals were performed. In the fi rst study: six animals were divided in two groups receiving 1mL PBS or CL (5 mg/mL) and were infected at d0 with P. falciparum (FUP strain). In the second study: 14 animals were used in six groups -three uninfected controls groups with 2 animals each receiving 1 mL PBS, 0.5 mL or 1 mL CL and three groups infected at d0 and that received the same injections (PBS group with 2 animals and CL groups with 3 animals each one). In both studies the injections were performed intravenously twice weekly from d0. Follow-up was performed. Histological examination of spleen and liver was performed at the end of the study. Results In the fi rst study, animals receiving CL had high parasitemias requiring antimalarial treatment, whereas animals receiving PBS controlled the infection. In the second experiment, infected animals receiving 0.5 mL CL showed parasitemia higher than the other two groups. In all infected animals, the temperature was related to parasitemia. Hemoglobin and hematocrit concentration decreased reaching minimum values during or after clearance of the parasite. The animals tolerated the CL injections, but in some cases signs of liver toxicity were observed on histopathology. Animals receiving CL showed decreased iron staining in the spleen. Conclusions Our results suggest that CL is able to promote higher parasitemias and could be an alternative to surgical splenectomy. Additional studies are needed to confi rm the data. Background Artemisinin resistant P. falciparum malaria has emerged in Western Cambodia and now has been observed in Thailand, Vietnam and Myanmar and Lao. In addition, there is a recent report of a Vietnamese patient, apparently infected with P. falciparum in Angola, who was unresponsive to artemisinin treatment. This makes it even more urgent to have baseline information on early parasite response to ACTs in African patients, the fi rst step in establishing surveillance for this important phenotype. Materials and methods Individual patient data from effi cacy trials conducted between 1999 and 2012 were shared with the Worldwide Antimalarial Resistance Network (WWARN) and pooled analyses conducted using standardized methodology. Factors aff ecting early parasitological response to treatment were investigated using logistic regression with study sites fi tted as a random eff ect. Results Data from 85 studies (N = 29,664) conducted in 27 countries with Artemether-lumefantrine (AL, n = 13,664), Artesunate-amodiaquine-fi xed dose combination (ASAQ-F; n = 4,097), Artesunateamodiaquine-co-blister combination (ASAQ-C; n = 2,505), Artesunateamodiaquine-loose combination (ASAQ-L; n = 4,096), and Di hydro artemisinin-piperaquine (DP; n = 4,492) were included. With all drugs tested, high baseline parasite density and fever were both independent predictors of persistent parasitemia on days 1, 2 and 3. Adjusted for these variables, patients from 1 to 5 years and from 5 to 12 years in areas of low/moderate transmission were at a 2-fold and 4-fold risk of persistent parasitemia on day 3 compared to patients of the same age-group in high transmission settings. Treatment with AL was associated with a higher risk of persistent parasitemia on day 1 (AOR = 1.57 [95% CI: 1.38-1.78], P < 0.001) and day 2 (AOR = 1.21 [95% CI: 1.01-1.45], P = 0.043) compared to treatment with DP. Treatment with ASAQ-L was also associated with a higher risk of persistent parasitemia on day 2 (AOR = 1.59 [95% CI: 1.16-2.18], P = 0.004) and day 3 (AOR = 2.62 [95% CI: 1.24-5.53], P = 0.012) compared to treatment with DP. Conclusions These results show no evidence of slow parasite clearance in these African studies. The greatest risk of slow clearance was observed in patients from areas of low/moderate transmission. The threshold for suspected diminished parasite susceptibility to artemisinins on day 3 was estimated to be 5%, much lower than the currently used World Health Organisation threshold of 10%. However, there are clear gaps in surveillance and any sites exceeding the day 3 parasite positivity rate of 5% should be further investigated.
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Acknowledgements A full list of the Worldwide Antimalarial Resistance Network ACT Africa baseline study group members can be found at: http://www.wwarn.org/partnerships/study-groups/ act-africa-baseline-study-group. Long-lasting insecticidal nets (LLINs) and indoor residual spraying (IRS) are the two main malaria prevention strategies in Ethiopia. Although both interventions have been shown to be eff ective in reducing malaria transmission when applied independently, there is confl icting evidence that the two in combination is better than either one alone. The main objectives of this trial are to determine the added protection value against malaria and to evaluate the cost-eff ectiveness when applying IRS and LLINs together, or LLINs or IRS independently. This trial will be conducted in Adami Tullu district of Oromia Regional State in Ethiopia from 2014 to 2016. The project will use a cluster randomized controlled trial, with four "arms": IRS+LLINs, LLINs alone, IRS alone and control (routine practice). The sample size includes 40 clusters in each arm, each cluster with 35-45 households. Each household and each inhabitant in the household will be given a unique identifi cation number. Households will be mapped using global positioning system. At the start of the trial, all households in the IRS+LLINs and LLINs alone "arms" of the study will be provided new LLINs free of charge. IRS with an insecticide (propoxur) will be applied in IRS+LLINs and IRS alone arms twice a year throughout the study. Each household will be visited weekly, and blood samples will be collected from each household member with fever or history of fever. Thick and thin blood smears will be taken by fi nger prick and rapid diagnostic tests will be used to detect malaria at fi eld level. Data on all self-reporting malaria patients attending health posts will be collected. The cost-eff ectiveness and entomological studies will be simultaneously conducted. Analysis will be based on intention to treat principle. Ethical clearance was obtained from the Ministry of Science and Technology in Ethiopia and the University of Bergen. This trial aims to provide evidence on the combined use of IRS and LLINs for malaria prevention. We aim to answer the following research questions: Can the combined use of LLINs and IRS signifi cantly reduce malaria incidence compared with the use of LLIN or IRS alone? And is the reduced incidence justifi ably compared to the added costs? Will the combined use of LLINs and IRS reduce vector density, infection, longevity and the entomological inoculation rate? Such data is crucial in order to maximize the impact of the intervention on malaria morbidity and mortality. Background Malaria elimination is a goal of many endemic countries with the ultimate goal of global malaria eradication. Based on the achievements the country has made over the last decade, Nepal has been preparing for a malaria pre-elimination phase since 2011 with the ambitious vision of a malaria-free Nepal by 2026. However, a number of challenges have been identifi ed in recent studies including high rates of relapse/re-infection with Plasmodium vivax [1] , persistence of Plasmodium falciparum and clinically suspected malaria, continuous import of malaria cases, underreporting of mixed infections (P. falciparum and P. vivax), and climate change [2] . In this study, we report, in addition, on altitudinal shifts of malaria vectors in Nepal. One of the defi ning challenges of controlling and eliminating Plasmodium vivax is the tendency to relapse. Months or even years after clearing the initial infection, new blood-stage infections can emerge from hypnozoites in the liver if they are not cleared with radical cure. The relapse phenomenon is further complicated by the fact that P. vivax infections exhibit diff erent patterns of relapse times in diff erent areas. The tropical Chesson variant has a short distribution, with most relapses occurring in the fi rst 3-4 months after initial infection. Other variants have an initial infection, early relapses, and then later relapses, 8-12 months, after the initial infection. Still others have relapses over a year after the initial infection, and some do not exhibit an initial infection at all. We construct a unifi ed mathematical model for the distribution of three important patterns, demonstrate how each distribution is well-suited to the local transmission dynamics in which it is observed, and discuss the implications for control and elimination. 
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Altitudinal shift of malaria vectors and malaria elimination in Nepal
Materials and methods
Materials and methods ASC and mBC responses were measured using a standardized B cell ELISPOT method, using fresh and frozen PBMC respectively, whilst antibody titre was measured using a standardized ELISA for AMA1. Multiparameter fl ow cytometry was also subsequently run using frozen PBMC to characterise total peripheral CD4+ Tfh populations and the AMA1-specifi c CD4+ T cell response. Results AMA1 specifi c ASC, mBC and antibody responses followed classical kinetics at a level comparable to those previously described, with ASC and antibody responses strongly correlating. Background Helminths and malaria parasites inhabit the same geo graphical areas and coinfection is frequently observed. The immunological interaction between helminth and malaria infections is highly relevant to disease control and elimination, yet is poorly understood and understudied. Chronic helminth infection causes immune hyporesponsiveness and stimulates anti-infl ammatory cytokine production, which in turn modulates the host immune response to malaria. In epidemiological studies, many data are confl icting with some reporting protective eff ects against malaria for Ascaris lumbricoides and Schistosoma haematobium while infection with hookworm or S. mansoni may increase the incidence of malaria and worsen pathology.
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Co-infection with
Materials and methods
We undertook a prospective study of schoolchildren aged 5-16 in an area endemic for schistosomiasis near Lambaréné in Gabon. 425 children were recruited and demographic data was collected. Laboratory analysis for P. falciparum malaria infection (thick blood smear and rapid test) and S. haematobium infection (urine microscopy) was performed and treatment was provided to infected children. Children were followed up locally for malaria-like symptoms, actively for two months and passively for a further 2 years. At recruitment, whole blood was collected into Paxgene tubes from a subset of children for transcriptional profi ling among uninfected (n = 12), S. haematobium infected (n = 16), malaria infected (asymptomatic, n = 8) or coinfected (n = 13) children. RNA was extracted, amplifi ed and hybridized to Illumina HT12v4 microarrays. Results In the full cohort age, gender and schistosomiasis were not associated with malaria and malaria incidence among these schoolchildren was 0.4 episodes per person per year. Analysis of the microarray data revealed monoinfection with either S. haematobium or malaria resulted in relatively insignifi cant changes to the transcriptome relative to healthy controls at the 10% false discovery level. There was also no diff erence in gene expression profi le between healthy controls and coinfected children. However, between malaria infected and coinfected children there were 240 diff erentially expressed genes with 180 genes upregulated and 60 downregulated in the coinfected group. Specifi c genes of relevance to malaria infection, including CD8a, were signifi cantly downregulated in malaria-infected compared to coinfected children.Pathway analysis revealed substantial modulation of gene expression in defence and immune responses and in particular modulation of genes in the Fcγ-receptor-mediated phagocytosis pathway. Conclusions Confi rmatory experiments are underway to confi rm these intriguing insights into the immunomodulatory eff ect of S. haematobium on P. falciparum malaria in a key population for public health intervention.
transmission. However recent reports indicate that vectors are increasingly biting outdoors in areas where coverage of insecticidetreated nets is high -potentially a sign of behavioural adaptation [1, 2] . Using whole genome deep sequencing, we investigated whether there is a genetic diff erence between indoor and outdoor-biting populations of An. gambiae s.s. Materials and methods An. gambiae s.s. were collected by human landing catches from indoor and outdoor locations approximately 60-200 m apart in The Gambia. Genomic analysis was performed on single-nucleotide polymorphisms (SNPs) ascertained from wholegenome sequencing. We examined the diversity, divergence and deviation from neutrality of diff erent genomic regions to look for evidence of genetic diff erentiation between the two populations. We also performed a genome-wide association study (GWAS) to test for any associations of SNPs with the outdoor-biting phenotype.
Results Estimates of population structure show weak diff erentiation between the two populations (F st = 0.00004). There was no diff erence in the pattern of nucleotide diversity and Tajima's D statistics between the two populations which exhibited variations within and between chromosomes. Linkage disequilibrium (LD) was low across all chromosomes, except for elevated peaks within inversions and centro-/ telomeric regions. With no known loci implicated in biting-behaviour, we examined all loci and defi ned a cut-off at P < 1 x 10 -5 for signifi cant associations yielding a total of 53 SNPs of interest. We found that most of these SNPs were in non-coding regions. Conclusions This is the fi rst study investigating the genetic diff erentiation between indoor and outdoor-biting populations. We detected very little genetic diff erences between the two populations except for a few SNPs that were identifi ed in the GWAS. These SNPs are currently under investigation in a comparison panel comprising of Ugandan samples. References is an antigen considered to be one of the leading malaria vaccine candidates. PvMSP-1 is immunogenic and evidences suggest that it is a target for protective immunity against asexual blood stages of malaria parasites. This study aims to evaluate the acquired cellular and antibody immune responses against PvMSP-1 in individuals exposed to malaria infections in a Brazilian malaria endemic area. Methods The study was carried out in Paragominas, Pará State, in the Brazilian Amazon. Blood samples were collected from 35 individuals with uncomplicated malaria. Peripheral blood mononuclear cells were isolated and the cellular proliferation and activation was analyzed in presence of 19 kDa fragment of MSP-1 (PvMSP-1 19 ) and P. falciparum PSS1 crude antigen. Antibodies IgE, IgM, IgG and IgG subclass and the levels of TNF-α, IFN-γ and IL-10 were measured by enzyme-linked immunosorbent assay (ELISA , Thomas Smith and morbidity of the disease. Sustaining these gains in the future will depend on the health system performance. Treatment provides individual benefi ts by curing infection and preventing progression to severe disease as well as community-level benefi ts by reducing the infectious reservoir and averting the emergence and spread of drug resistance. However many patients with malaria do not access care, providers do not always comply with treatment guidelines, so patients do not necessarily receive the correct regimen. Even when the correct regimen is administered there is concern that patients will not adhere, leading both to treatment failures and potentially to the spread of drug resistance.
Methods and results
We propose a framework to assess the eff ectiveness of malaria case management and apply it to derive estimates for 42 high-burden Sub-Saharan African countries. We explicitly consider implications of treatment seeking, source of treatment, systems compliance with the recommended antimalarial treatment, adherence with the drug regimen, and quality of the antimalarial medication on eff ectiveness of malaria case management. Country-specifi c parameters are populated from the Demographic and Health Surveys and other published sources. We assess the relative importance of these factors on the level of eff ective coverage within a given setting and the variation in these systems indicators across the region. Our fi ndings suggest that overall only about two-thirds of fevers for which treatment is sought are treated eff ectively; that is about 40% of treatments fail to clear parasitaemia. There is however a lot of variation in the eff ectiveness of malaria case management across the region. Diff erent factors account for ineffi ciencies in diff erent countries. Conclusions The patterns of inter-country variation suggest that these system failures are amenable to change. Identifying and remedying these should become key priority areas for malaria control policy in the region. Signifi cant losses in effi cacy of treatment are found even in countries with a relatively high quality of care. In general there is a need for more valid, reliable, and representative data on these important quantities. Treatment is an important determinant of the burden of malaria disease, and of the incremental benefi ts of other interventions, but has often been disregarded in resource allocation decisions. Including these aspects would allow policy makers to make decisions on the basis of the specifi c conditions of the settings where malaria control interventions are actually needed. Most antimalarial drugs face decreased effi cacy due to the emergence of resistant parasites. Therefore, the discovery of new antimalarial medicines is focused on new drugs that act by novel mechanisms and are active against diff erent P. falciparum development stages. Screening of a focused compound library for antiparasitic activity, lead to identifi cation of a novel class of compounds with activity against P. falciparum, 2-aminopyridines. The selected hits were validated and subjected to a lead optimization program resulting in the pre-clinical candidate MMV390048. Here we report an unbiased chemoproteomics strategy for the identifi cation of targets of MMV390048. An analogue of MMV390048 containing a primary amine function for immobilization in a permissive position was synthesized and covalently immobilized on sepharose beads. Affi nity capturing of potential target proteins from a P. falciparum blood stage extract was performed in the absence and presence of an excess of MMV390048 in the extract to delineate target proteins for which capturing is competitively inhibited. All proteins captured by the beads were quantifi ed by isotope tagging of tryptic peptides followed by LC-MS/MS. Notably MMV390048 competitively inhibited the binding of only a single protein, P. falciparum PI4 kinase, to the beads. However, the immobilization of a drug compound via a linker may not be compatible with the binding to all of its targets.
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Therefore, we also performed a capturing experiment with kinobeads, which represent a combination of immobilized promiscuous ATP competitive kinase inhibitors (Bantscheff et al., 2007). As in the previous experiment, PfPI4K was the only P. falciparum protein which exhibited a reduction of bead binding upon the addition of MMV390048 to the extract. Knowledge of the target will accelerate the drug discovery process.
Background A newly published genus-specifi c PCR targeting mitochon drial genome was highly sensitive and specifi c (Haanshuus et al. 2013). The aim of the study was to decrease the laboratory time without impairing sensitivity or specifi city, by converting the conventional PCR to real-time PCR using SYBR dye. A second aim was to include speciesspecifi c assays to be optionally run together with the genus-specifi c real-time assay. , though with separate master mixes for each target. As opposed to the conventional PCR the assays could be optionally run together, as the master mixes were optimized to fi t the same standard cycling parameters. The material consisted of 26 confi rmed positives and 82 negative ones. In addition a ten-folded dilution series of a standardized reference sample was included. Limit of detection was determined. All the positives and the dilution series were analyzed in duplicates. Threshold cycle (Ct) cutoff value was set at 35.
Materials and methods
Results
The mitochondrial genus-specifi c real-time assay detected 24 of the 26 positives in both duplicates (17 P. falciparum, fi ve P. vivax, one P. ovale, and one mixed infection with P. falciparum and P. malariae). A submicroscopic P. malariae was not positive in any of the duplicates, while a P. falciparum sample was positive in one out of two. The latter sample had previously not been detected by any 18S PCR assays (Haanshuus et al. 2013). The limit of detection was 0.2-2 parasite/μl. (The conventional genus-specifi c assay had a sensitivity of 0.5 p/μl). The specifi city was 100%. The 18S species-specifi c assays detected as well 24 out of the 26 positives in both duplicates, with 100% specifi city (no cross-binding). The submicroscopic P. malariae and the mentioned P. falciparum were not detected in any of the duplicates. The sensitivity was 100% screening the negatives. Conclusions The real-time assays showed similar high sensitivities and specifi cities as its conventional counterparts, though less timeconsuming and more practical and user-friendly both for research purposes and clinical diagnostics. The sensitive and effi cient genusspecifi c assay is ideal for screening large sample sizes; however, the species-specifi c assays can be optionally run simultaneously which is an advantage especially in clinical diagnostics.
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Malaria prevalence among patients with acute undiff erentiated fever in secondary hospitals in India Christel Gill Haanshuus 20,000 to 200,000. The aim of this study was to identify the malaria prevalence among patients with acute undiff erentiated fever in rural hospitals in India. Materials and methods During April 2011-November 2012, 1564 patients aged >5 years were included in a larger fever study from seven secondary hospitals in India located in Assam (Tezpur), Bihar (Raxaul), Chhattisgarh (Mungeli), Maharashtra (Ratnagiri), Andhra Pradesh (Anantapur) and Tamil Nadu (Oddanchatram and Ambur). Routine microscopy, genus-specifi c mitochondrial PCR and the rapid immunochromatographic test (RDT) Parahit Total™ (Span Diagnostics Ltd, Surat, India) were performed. Species-specifi c 18S PCR or sequencing was performed on genus PCR positive samples. Samples with discordancy between PCR and RDT were retested by PCR from the extraction step. PCR was considered as gold standard. Results EDTA blood for PCR was available from 1416 patients and 19% were malaria PCR positive. The prevalence ranged from lowest 6% in Oddanchatram (South India) to highest 35% in Ratnagiri (West India). P. falciparum single infection was detected in 46%, 38% had P. vivax, and 11% mixed infections with P. falciparum and P. vivax. P. malariae was detected in 5%. Compared with PCR, the sensitivity of the RDT was 24% and specifi city 99%. The sensitivity of microscopy was 29% and specifi city 98%. A trend of incorrectly diagnosing P. falciparum as P. vivax by microscopy was found. Conclusions Our fi ndings support that malaria is an important diff erential diagnosis in acute undiff erentiated fever in all parts of India, and PCR identifi ed a high level of submicroscopic malaria. The very low sensitivity of the RDT emphasizes the importance of choosing a test with high sensitivity, for which WHO's validation of RDTs should be used. Background Prior to the commencement of a large-scale malaria intervention study on Rusinga Island, western Kenya, intensive baseline surveillance of the mosquito population was performed using odourbaited traps. The survey aimed to determine the relative abundance and species composition of malaria vectors, and to measure seasonal and spatial heterogeneity in populations. Human malaria prevalence was combined with entomological data to provide information about malaria transmission risk before the intervention began. Materials and methods From September 2012 until June 2013, mosquito monitoring took place over successive six-week sampling periods. MM-X traps baited with attractant lures and carbon dioxide were used to collect mosquitoes from inside and outside houses, and a new random sample of 80 households was drawn for each sampling round. During the baseline period, malaria prevalence was measured twice in a randomly selected 10% of the human population. A QuickBird satellite image and digital elevation map were used to describe environmental features of the island. Mosquitoes were initially identifi ed on the basis of morphology and anophelines were processed by PCR to confi rm species identifi cations. Results Odour-baited MM-X traps proved to be a good tool for monitoring malaria vectors inside and outside houses. Using this tool a marked temporal and spatial heterogeneity was described for the malaria vector species Anopheles gambiae s.s., An. arabiensis and An. funestus. Regions of potentially high malaria transmission intensity were identifi ed after mapping the distributions of malaria mosquitoes and Plasmodium-positive persons. Despite studying a range of environmental and topographical features, no strong associations were found between environmental variables and the presence or absence of adult Anopheles. Conclusions Malaria vectors and malaria prevalence are not homogeneously distributed across Rusinga Island; the risk of malaria transmission is therefore greater in some areas than others. The fi nding that environmental features were not closely associated with adult malaria vector distribution, indicates that other factors, such as house construction or the presence of livestock, may play a more important role in the decision of a female anopheline to approach the domestic environment of a particular house in search of a blood meal. The fi ndings of this study demonstrate how trans-disciplinary data can be integrated to provide a better understanding of mosquito population dynamics and malaria transmission risk. Intensive mosquito monitoring before the commencement of, as well as during, a large-scale malaria intervention study, contributes valuable information which will be used in describing the eventual impact of the intervention. Background Sickle cell (HbS) and β 0 -thalassaemia, two common malaria-protective β-globin mutations, represent impressive examples of human adaptation to infectious disease. Highly prevalent in SubSaharan Africa and the Mediterranean, respectively, these mutations display contrasting patterns in their haplotype structure and distribution. The majority of HbS is associated with fi ve major restriction fragment length polymorphism patterns that exhibit remarkable geographical specifi city. By contrast, β 0 -thalassaemia, which can result from several diff erent mutations, is found on many more haplotypes whose distributions considerably overlap. Here, we shed light on the evolutionary and demographic factors that likely gave rise to such diff erences, despite malaria being a common selective force. Methods A stochastic population genetic model, which also incorporated individual-based processes, was developed to simulate and track the evolution of HbS and β 0 -thalassaemia haplotypes, separately, in a meta-population. Under no a priori assumptions, the infl uence of mutation, gene conversion, fi tness variation and population structure on the spread of individual mutant β-globin haplotypes through a network was investigated. Results The outcomes resembling the present-day patterns of HbS and β 0 -thalassaemia haplotypes were obtained under somewhat restrictive, and indeed distinct, parameter combinations. For both mutations, we consistently observed allelic exclusion, whereby subpopulations already containing one haplotype at a high frequency were rarely taken over by another. This has several implications. First, the formation of the present-day HbS haplotype pattern requires minimal gene fl ow and strong population structure such that multiple alleles can arise and spread in distinct regions of the meta-population without interference from each other. By contrast, the overlapping of haplotypes, as for β 0 -thalassaemia, was more common when movement through the network was less restricted to allow separately dispersing haplotypes to meet when they are still at low frequency. Finally, as gene conversion can occur only in subpopulations already polymorphic for a mutation, haplotypes arising through gene conversion are frequently excluded unless fi tness is suffi ciently varied. Conclusion We have developed a generic framework to explore the processes aff ecting the evolution and spread of genetic diseases, and applied it to the study of the haplotype evolution of two malariaprotective disorders. In doing so, we have been able to delineate the conditions under which the observed present-day patterns of HbS and β 0 -thalassaemia haplotypes are most probable, and identifi ed the major processes contributing, under malaria selection, to their haplotypic evolution. The model is highly versatile and can be used to explore both basic evolutionary biology questions and applied public health enquiries. Background Recent emergence of artemisinin resistant Plasmodium falciparum in Southeast Asia has threatened malaria control eff orts across the globe. Clinical resistance is characterized by reduced rates of parasite clearance following treatment; yet in vitro phenotypes of artemisinin resistance suitable for elucidating molecular mechanisms of resistance remain elusive. Materials and methods In this study we culture adapted and characterized a series of P. falciparum clones from Cambodia; these included parasites from cases with reduced parasite clearance rates in vivo. In vitro artemisinin resistance phenotypes were assessed by using T 0 3 H-hypoxanthine assays, a novel parasite clearance assay, microscopy and fl ow cytometry to characterize intraerythrocytic development, and limiting dilution to assess parasite viability. Results Detailed phenotypic characterization of artemisinin resistant P. falciparum revealed a series of complex phenotypes that included 4-8 fold resistance to multiple artemisinin derivatives in vitro that is stable for >1 year. By using a novel parasite clearance assay we observed reduced parasite reduction rates (PRRs) for resistant clones in vitro and these were positively correlated with parasitemia clearance half-lives in vivo. Most remarkably we discovered an altered pattern of intraerythrocytic development of the artemisinin resistant clones of P. falciparum. In the absence of any drug pressure, resistant clones exhibited a prolonged phase of ring stage development followed by a signifi cantly shortened trophozoite stage of development. Given that ring stages are the most resistant to inhibition by artemisinin and the trophozoites are the most susceptible, this novel phenotypic resistance to artemisinin results in reduced exposure to drug at the most sensitive stage of development (trophozoite). Additional confi rmation of the selective pressure driving this phenotype is one resistant clone exhibited a 12 hour shorter erythrocytic life cycle that also compressed the trophozoite stage of development. Conclusions The evolution of artemisinin resistance appears to select for altered intraerythrocytic development such that the most susceptible stage of development is signifi cantly reduced in the cell cycle. Our data demonstrate that altered intraerythrocytic development is a novel mechanism of phenotypic resistance to artemisinin antimalarial drugs.
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Spatial heterogeneity of malaria vectors and malaria transmission risk estimated using odour-baited mosquito traps
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Understanding the haplotypic diversity and distribution of malaria-protective β-globin mutations
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The eff ect of artemisinin-combination treatment options on P. falciparum gametocyte carriage: a pooled analysis of individual patient data Georgina Humphreys Background Artemisinin combination therapies (ACT) rapidly clear the asexual parasite population in infected individuals. In addition, the artemisinin components specifi cally kill early stages of gametocyte development and have an incomplete eff ect against mature gametocytes. These properties mean that ACT may play a critical role in reducing the transmission of malaria and decreasing the spread of drug resistant parasites. However, diff erent ACT options may have diff erential eff ects on gametocyte carriage and the production of gametocytes during infections is infl uenced by parasite, human and environmental factors. Material and methods A systematic search of the literature was conducted to identify all studies published between 1960 and March 2014, in which patients were enrolled and treated with antimalarials and where gametocyte data were recorded. An a priori data analysis plan was developed to identify factors associated with gametocyte prevalence and density prior to treatment and following treatment with ACT. Individual patient data from over 100 published studies (n > 50,000) were collated, curated and included in the analysis, with data from 21 African and 6 Asian countries. Criteria for the quality of gametocyte assessments were ascribed to the various studies. Results Before September 2014, we will have determined the eff ects of asexual parasite density, age, transmission intensity and haemoglobin concentration on enrolment gametocyte prevalence and density. We will further present post-treatment gametocyte prevalence, density and carriage time in relation to ACT regimen (artemether-lumefantrine, amodiaquine-artesunate, dihydroartemisinin-piperaquine, and mefl oquine artesunate), parasite clearance time, transmission intensity and human host factors. Acknowledgements A full list of the Worldwide Antimalarial Resistance Network Gametocyte Carriage Study Group members can be found at: http://www.wwarn.org/partnerships/study-groups/ gametocyte-carriage-study-group. Background Pailin Province in Cambodia is a malaria pre-elimination setting, with very low levels of Plasmodium transmission. Malaria elimination in this location is a priority, due to the confi rmed presence of artemisinin-resistant parasites. The objective of this study was to evaluate the feasibility of a focal screening and treatment (FSAT) approach using microscopy, rapid diagnostic tests (RDT) and polymerase chain reaction (PCR) around passively-detected Plasmodium infections, as well as to assess the impact of FSAT in identifying and eliminating the asymptomatic reservoirs of Plasmodium in the population. Materials and methods Following passive identifi cation of Plasmodium infected patients by health staff with RDT, targeted screening was conducted either i) among all additional residents of the index case household (nHH = 255); ii) all residents of the fi ve households closest to the index household (nHH = 45); or iii) all residents of the closest 10 households (nHH = 80). Screening was conducted within three days of the index case being identifi ed. In addition, 60 households within the health centre catchment population were randomly selected for screening. Half of these households were selected from villages with >10 confi rmed malaria cases in 2013, and half from villages <10 cases. Individuals provided a blood sample onsite for microscopy, RDT, and PCR analysis. Plasmodium genotyping analysis was conducted to investigate whether index and non-index infections are linked. Results A total of 270 index cases (symptomatic, RDT-positive) presented to health workers over the nine month study period, prompting screening activities in the community. Of a total 1869 non-index cases tested by PCR, 43 (2.3%) were positive for Plasmodium infection; 25 P. falciparum, 16 P. vivax and two mixed infections. We present these PCR data stratifi ed by household selection criteria (index, nearby and randomly selected) to explore if or at what level FSAT around passivelydetected symptomatic infections is useful in this context. These data are also presented for each diagnostic tool. Full details of risk factors for symptomatic and asymptomatic infection in this population will be presented. These data provide additional evidence to assess the usefulness of focal screening around symptomatic malaria cases as a strategy to identify further asymptomatic infections in the population. The potential eff ectiveness of this approach in a malaria elimination programme is discussed. Control of malaria relies heavily on the use of insecticides and resistance in malaria vectors such as An. funestus, is a serious threat to the success of these control tools. Recent studies have shown that the duplicated cytochrome P450s, CYP6P9a and CYP6P9b shown to confer pyrethroid resistance, vary extensively in their allelic distributions across Africa and this is possibly impacting distribution of pyrethroid resistance in this specie. Polymorphism in CYP6P9a and b in resistant mosquitoes from Benin, Uganda, Malawi, Mozambique and susceptible strain (FANG) was mapped. Models of these genes were constructed using CYP3A4-1TQN and 3D insecticides docked using GOLD. Membranes from these genes co-expressed with CPR were screened with fl uorescent probes. Kinetic parameters and IC 50 against ten insecticides were established with the probe diethoxyfl uorescein. Metabolism assay was carried out against pyrethroids; time-and NADPH-dependent depletion and kinetic parameters determined. Site-directed mutagenesis was employed to change some key amino acids from resistant individuals to what is obtainable in the susceptible individuals, proteins expressed and metabolism assays carried out. Docking results predict higher activity in alleles from Southern Africa compared with those from other regions. FANG alleles have the lowest activity. With the exception of FANG, the membranes metabolise diethoxyfl uorescein very well, with the lowest Km and highest Vmax obtained from the Southern African alleles. Low IC 50 was obtained with pyrethroid and high IC 50 with carbamates and DDT. The membranes metabolise type I and II pyrethroids with resistant alleles from Southern Africa having the highest activity, consistent with the highest resistance level to pyrethroids in this region. The susceptible strain is incapable of signifi cant metabolism against pyrethroids tested. Metabolism assays using the mutants of CYP6P9 and b identifi ed mutants incapable of appreciable metabolism of permethrin and deltamethrin. The signifi cant diff erences observed in the activity of diff erent alleles of CYP6P9a and b probably explain the variation in distribution of pyrethroids resistance in Africa. Kinetic analysis is being carried out to establish steady state parameters using the proteins from the wild type and the mutants against pyrethroids. It's hoped that these results will pinpoint the causative mutations responsible for resistance pattern with pyrethroids so that diagnostic tools could be established to easily detect this kind of resistance. Malaria is one of the major public health concerns due to re-emergence of the disease in Bangladesh in the 1990s. Currently it is endemic in 13 out of 64 administrative districts bordering India and Myanmar. Three hill tract districts (Khagrachhari, Rangmati, Bandarban) in the southeastern part of the country report the highest incidences. The overall prevalence rate is 3.1% in the 13 endemic districts and 11% in 3 hill districts. BRAC initiated a pilot malaria control project in one of these hill districts in 1998. By 2004, the program expanded to all three hill tract districts covering 1.4 million population with the support from National Malaria Control Programme and with technical support from WHO. Later in 2007, BRAC led consortium of 20 partner NGOs started comprehensive implementation of the programme in all endemic districts with a population of 11 million in collaboration with the government and with fi nancial support from the Global Fund to fi ght AIDS, TB and Malaria (GFATM). The aim was to control the vector, to prevent disease transmission, and to provide early diagnosis and prompt eff ective treatment services to reduce morbidity and mortality. Currently Long Lasting Insecticidal Nets (LLIN) are being distributed and ordinary bed nets are being treated with insecticide (Insecticide Treated Net-ITN) to the endemic districts. BRAC has selected female Community Health Workers from their own community and involved them to reach the poor and people living in areas with limited access to treatment services supplementing the government's health care system. They provide home-based care of malaria diagnosis and treatment. They also provide malaria related information especially on malaria transmission, bed net usage, malaria symptoms and available treatment services at community level. Diff erent sensitization meetings are conducted with opinion and religious leaders, local government and civil society representatives to increase awareness on malaria prevention and management. A recent survey showed that net utilization rate among children under fi ve is 90% and among pregnant women is 85% in malaria endemic region. The national disease specifi c report shows a substantial decline in malaria cases from the baseline year 2008 (84,690 cases) to 2013 (26,891 cases), a 68% reduction of cases. Increased use rate of LLIN/ITN along with early seeking of home based malaria management is the key to success in malaria control. 8-aminoquinoline drugs are critical to malaria elimination campaigns due to their unique ability to kill the dormant liver stage form of Plasmodium vivax. Due to the potential for hemolytic reactions in G6PD-defi cient patients, safe administration of these drugs requires assessing a person's glucose-6-phosphate dehydrogenase (G6PD) status. Quantitative and qualitative phenotypic tests that assess overall G6PD activity within a blood sample are generally able to distinguish between G6PD-normal and defi cient patients, not factoring in red blood cell (RBC) count and hemoglobin level. A cytofl uorimetric assay (Shah et al. 2012) allows for screening of G6PD activity within individual RBCs and identifi es heterozygous females. This method enables the discrimination of distinct cell populations based on their G6PD activity, estimating the actual proportion of defi cient RBCs that are likely to hemolyze during drug treatment. As part of the study, we enhanced the G6PD classifi cation method by analyzing data from the cytofl uorimetric assay with a software tool developed at PATH. This software tool not only mitigates for variations in measurements generated by diff erent fl ow cytometers, but also implements a metric for a more quantitative interpretation of cytochemical staining results. PATH developed the software tool by correlating enzyme activity (G-6-PDH Kit, Trinity Biotech), genotypic information, and complete blood cell count data with the distinct G6PD activity measured by fl ow cytometry. As an additional level of validation, the software tool is undergoing blind testing with several hundred subsequent samples collected from multiple international sites. PATH plans to make the software publicly available and hosted online to aid clinical and research studies in determining G6PD status. Plasmodium vivax infects human reticulocytes through a major pathway that requires interaction between an apical parasite protein, the Duff y binding protein (region II, DBPII) and its cognate receptor on reticulocytes, the Duff y antigen receptor for chemokines (DARC). Although most people naturally exposed to P. vivax fail to develop antibodies that inhibit the DBPII-DARC interaction, the genetic factors that modulate humoral responsiveness are poorly characterized. Aiming to investigate if DBPII non-responsiveness could be HLA class II-linked (DRB1, DQB1 and DQA1), we carried-out an open cohort study among 340 non-related volunteers in an agricultural settlement of the Brazilian Amazon; three cross-sectional surveys were conducted at 6-month intervals, and 240 out of 340 (71%) subjects had consecutive samples. At enrolment, 40.9% of the study population had DBPII IgG antibodies, as measured by conventional serology (ELISA); two alleles at HLA-DR locus (DRB1*10:01 and DRB1*14:02) were negatively associated with the antibody response, while two alleles at HLA-DQ locus (DQB1*02:02 and DQA1*01:03) were positively associated with antibody response. The 12-month follow-up study confi rmed that those alleles associated with positive antibody response were also associated with the persistence of this specifi c antibody response. Further, we investigated whether HLA class II polymorphisms would infl uence the functional proprieties of DBPII antibodies (BIAbs, binding inhibitory antibodies), as assessed by the COS-7 cytoadherence assay. The results demonstrated that four alleles were associated with the presence (DRB1*07:01; DQB1*02:02, DQA1*02:01) or absence (DRB1*16:02) of DBPII BIAbs response. Taken together, this is the fi rst demonstration that HLA class II polymorphisms might infl uence the frequency and stability of the DBPII immune response. Due to the relevance of these fi ndings for vaccines now in development, it would be pertinent to investigate whether such an association exists in other P. vivax malaria endemic areas. Here, we demonstrated that activated as well as "atypical" memory B cells (MBCs) are expanded in peripheral blood of Pv-exposed individuals, but their frequencies were not associated with acute infection. Aiming to investigate the association between peripheral B cells subsets and Pv-specifi c antibodies, we further followed-up 34 individuals exposed to P. vivax in the Brazilian Amazon area, an area of markedly unstable malaria transmission; after three cross-sectional survey (at 6-months intervals), ELISA-detected specifi c IgG (AMA-1, MSP1-19, DBPII) allowed the classifi cation of those individuals as non-responder (NR), temporary (TR) or persistent responder (PR). For AMA-1 and MSP1-19 serological groups, the frequencies of MBCs (classical and atypical) and plasma cells (PCs) were similar among the groups. For DBPII group, we found a trend toward decreases classical MBCs according to the antibody response (NR>TR>PR). On the other hand, the frequencies of atypical MBCs increased according to the presence and persistence of DBPII antibody response (PR>TR>NR). Altogether, these results showed that atypical MBCs are expanded in Pv-exposed individuals (infected and noninfected), and it seems to be associated with the persistence of DBPII antibody response. Although preliminary, these results suggest that atypical MBCs contribute in generation of malarial antibody responses and provide insight into the role of atypical MBCs in P. vivax malaria immunity. Acknowledgements Supported by: FAPEMIG, FIOCRUZ, PAPES VI/ FIOCRUZ. Long-lasting insecticidal nets (LLINs) and indoor residual spraying (IRS) interventions can reduce malaria transmission by targeting mosquitoes when they feed upon sleeping humans and/or when they rest inside houses, livestock shelters or other man-made structures. However, many malaria vector species can maintain robust transmission, despite high coverage of LLINs/IRS containing insecticides to which they are physiologically fully susceptible, because they exhibit one or more behaviours that defi ne the biological limits of achievable impact with these interventions: (1) natural or insecticide-induced avoidance of contact with treated surfaces within houses and early exit from them, minimizing exposure hazard of vectors which feed indoors upon humans, (2) feeding upon humans when they are active and unprotected outdoors, attenuating personal protection and any consequent community-wide suppression of transmission, (3) feeding upon animals, minimizing contact with insecticides targeted at humans or houses, (4) resting outdoors, away from insecticide-treated surfaces of nets, walls and roofs. Residual malaria transmission is therefore defi ned as all forms of transmission that can persist after achieving full population-wide coverage with eff ective LLIN and/or IRS containing active ingredients to which local vector populations are fully susceptible. Residual transmission is suffi ciently intense across most of the tropics to render malaria elimination infeasible without new or improved vector control methods. Many novel or improved vector control strategies to address residual transmission are emerging that either (1) enhance control of adult vectors that enter houses to feed and/or rest by killing, repelling or excluding them, (2) kill or repel adult mosquitoes when they attack people outdoors, (3) kill adult mosquitoes when they attack livestock, (4) kill adult mosquitoes when they feed upon sugar, or (5) kill immature mosquitoes at aquatic habitats. However, none of these options has suffi cient supporting evidence to justify full-scale programmatic implementation so concerted investment in their rigorous selection, development and evaluation is required over the coming decade to enable control and, ultimately, elimination of residual malaria transmission. In the meantime, national programmes may assess options for addressing residual transmission under programmatic conditions through exploratory pilot studies with strong monitoring, evaluation and operational research components, similarly to the Onchocerciasis Control Programme. Malaria is a global health problem that causes signifi cant mortality and morbidity, with more than 1 million deaths per year caused by P. falciparum. Most antimalarial drugs face decreased effi cacy due to the spread of resistance. Most of the current compounds used for malaria treatment share related mechanisms of action so, there is an urgent need to identify new tractable targets to enable next generation of antimalarial drugs. The malaria drug discovery community has embraced phenotypic screening approaches as the strategy of choice for the generation of novel chemical starting points for Lead Optimization programs. Determining the mode of action for novel whole cell hits remains a challenge, but new technologies, including genetics, chemoinformatics and proteomics are proving successful. A chemical proteomics platform aimed at identifying antimalarial targets has been established. This platform is supported by The Bill & Melinda Gates Foundation and encompasses chemical probe synthesis, biological material preparation, pull down experiments and LC-MS protein-lead family characterization for chemical families of interest. Candidate scaff olds to be investigated through this platform are selected based on their biological profi le by a join Steering Committee constituted by both GSK and BMGF members.
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Development of a new software tool and analysis method to improve determination of G6PD status
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Characterization of Anopheline unique peroxidase and its role in the regulation of Plasmodium development Mithilesh Kajla
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Collaborative approaches for Target ID in neglected diseases: identifying new antimalarial targets
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The neuropathology of canine cerebral babesiosis compared to human cerebral malaria Andrew Leisewitz infection in dogs with Babesia rossi causes cerebral disease in some cases [2] . This disease demonstrates both similarities and diff erences to human malarial and comparisons may be of value in elucidating the pathogenesis of this serious complication in both hosts [3] . Materials and methods Post mortem brains collected from 50 natural cases of canine babesiosis showing clinical signs of cerebral involvement were collected and evaluated grossly and using light and electron microscopy. Results Grossly visible lesions (seen in 31/50) were classifi ed as global (16/50) or regional (34/50). Global lesions were diff use swelling and diff use cerebral congestion or pallor. Multifocal petechial haemorrhages and white matter malacia appeared more regional. There were 18/50 cases that had a grossly appreciable oedema. Histological lesions appeared in a spectrum of severity, and included very localized endothelial injury. Babesia-parasitised red cell sequestration was a feature in some sections. Early lesions were multifocal and strictly associated with the microvasculature. Intermediate lesions were characterized by perivascular haemorrhage and some neutrophil infi ltration. Advanced lesions were locally extensive and similar in appearance to haemorrhagic infarction. Ultrastructural evidence of cytoadherence between erythrocytes and capillary endothelium was demonstrated. Endothelial cell necrosis occurred early in the development of the lesions before neuronal and glial changes. Conclusions The endothelial injury, parasitized red cell packing and perivascular haemorrhage showed some similarities to the neuropathology of human CM. However the large haemorrhagic infarctions and clinical presentation with almost 100% mortality of dogs presenting with cerebral babesiosis were key diff erences. References The project "Ethiopian Malaria Prediction System" implemented from 2007 to 2012 combined new population-based malaria transmission information with climate and land use variability data to develop an early warning tool to predict malaria epidemics in Ethiopia. Scientists from Ethiopia and Norway collaborated to incorporate climate variability and forecast information for malaria epidemics. Our study shows that the association between weather and malaria is complex. Statistical models can predict malaria for large areas. However, as malaria transmission varies and depends on local environmental conditions, we need to have good and local knowledge about each area. However, weather variability is the main driver of malaria in Ethiopia. While the generation of precipitation depends on local ascent and cooling of the air, our research provided new data on the transport of moisture into the country that may improve weather forecasting. We developed a new classifi cation of climate zones, have mapped drought episodes in Ethiopia during the last decades, and have improved seasonal weather forecasting. Our hydrology studies show that potential climate change diff ers among the Ethiopian river basins, with river fl ows being sensitive to variations in rainfall, and less to temperature changes.
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Strengthening malaria and climate research in Ethiopia
The computer model, Open Malaria Warning, incorporates hydrological, meteorological, mosquito-breeding, land-use data, and cattle densities to fi nd out when and where outbreaks are likely to occur. We validated the model with data for malaria transmission in the highlands and lowlands, characterizing malaria transmission over some years in both highlands and lowlands. This provided us with new knowledge on malaria transmission in Ethiopia, how intense the seasonal transmission is, and how malaria occurs in diff erent populations and areas. Our study showed that indigenous malaria transmission during a non-epidemic year takes place above 2000 m altitude. We also showed the ideal temperature for malaria transmission is about 25°C, underlining that global warming may lead to increased risk of malaria in highland areas, and less in the lowlands with already high average temperatures. However, to validate such models, there is a need for several years of active monitoring of malaria cases and mosquito densities. Unfortunately, such data is rare in Africa, and we need to invest in long-term monitoring of malaria transmission. Background Nigeria and the Democratic Republic of Congo (DRC) together account for one-third of the estimated global total of malaria cases and 40% of malaria deaths. Improving health system performance in these countries is critical for reducing the global malaria burden. In both countries, fever treatment-seeking in the private sector is very common. Antimalarial medicine outlet surveys conducted in Nigeria and the DRC in 2009 documented antimalarial markets dominated by informal drug stores and high non-artemisinin monotherapy (non-AMT) availability and market share, as well as moderate availability of oral AMT. 2011 fi ndings from Nigeria showed improved artemisinin combination therapy (ACT) availability and market share, but continued availability and distribution of oral AMT. 2013 data were collected to inform and monitor ongoing strategy and funding decisions to improve malaria case management. Materials and methods Antimalarial medicine outlet surveys were conducted as part of the ACTwatch project (www.actwatch.info) in Nigeria and the DRC in 2013. A census of all outlets with the potential to sell/distribute antimalarials was conducted within a representative sample of clusters (national in Nigeria, Kinshasa & Katanga provinces in the DRC). Drug information, sale/distribution in the previous week, and retail price were collected for every antimalarial in stock. Product and distribution information was used to calculate relative market share using the adult equivalent treatment dose as the unit of analysis. Results The overwhelming majority of antimalarial-stocking outlets in the DRC and Nigeria were drug stores. In both countries, non-AMT (quinine in the DRC, chloroquine in Nigeria) and ACT were commonly in stock among antimalarial-stocking drug stores. While ACT availability was high, many drug stores in both countries were stocking non-quality-assured (QA) ACT. Oral AMT was commonly available among drug stores in Nigeria, but very rarely available in the DRC. The vast majority of antimalarials sold/distributed across study sites were distributed through drug stores. ACT (including non-QA ACT) accounted for less than half of the antimalarial market share in both countries. Non-AMT (SP, quinine, chloroquine) accounted for more than half of the market share across study sites. Conclusions Informal drug stores continue to dominate the antimalarial markets in the DRC and Nigeria in terms of absolute number of service delivery points, and sale/distribution of treatments. Consumers seeking care at antimalarial-stocking drug stores will commonly fi nd both non-AMT and ACT available. However, non-QA ACT is frequently available and distributed. Oral AMT availability continues to be of concern in Nigeria. Background Despite signifi cant advances made in the prevention and treatment of malaria in recent years, these successes continue to fall short of the World Health Organization (WHO) goals for malaria control and elimination. For elimination strategies to be eff ective, limited disease transmission, achieved through rapid reduction in infectious parasite reservoir and decreased gametocyte carriage, will be critical. Artemisinin-based combination therapy (ACT) forms the cornerstone of WHO-recommended treatment for uncomplicated Plasmodium falciparum malaria, and in combination with other eff ective interventions will undoubtedly play a vital role in elimination programmes. The gametocytocidal properties of ACTs are a bonus attribute; there is epidemiological evidence of reductions in malaria incidence and transmission in African regions since the introduction of these agents. Many studies and analyses have specifi cally investigated the eff ects of artemether-lumefantrine (AL) on gametocyte carriage. Materials and methods A systematic review of 62 articles published between 1998 and January 2014 was done which compares eff ects of AL on gametocyte carriage and malaria transmission with other ACTs and non-ACTs. AL was assessed based on its widespread usage of ACTs recommended by WHO, in the treatment for uncomplicated P. falciparum malaria in several African countries and the high number of clinical trials that have evaluated the product. Impact of AL on population gametocyte carriage and potential future role of AL in malaria elimination initiatives are also considered. Results The gametocytocidal eff ect of AL was proportionately consis tent across the studies reviewed, despite inherent diffi culties in comparing data from a range of studies that utilized diff erent diagnostic approaches to assess baseline gametocyte counts and diff erences in study designs. However, the specifi c place of AL is the subject of ongoing research and will be dependent on its use in combination with other intervention measures, rational use of the product, interaction with other medicinal agents in situations of malaria co-infections and comorbidities, and demographic diff erences. Use of ACTs like AL in malaria elimination strategies will therefore require balancing potential increased roll out with rational use and protection against resistance development. Conclusion AL (along with other ACTs) will continue to play a vital role in treatment of malaria by rapidly clearing asexual parasite load and reducing gametocyte carriage in both symptomatic patients and asymptomatic carriers. Consequently, AL, an ACT with this signifi cant dual activity on asexual and sexual parasite forms, can help shrink the infectious parasite reservoir that will in turn reduce infection of mosquitoes and ultimately minimize malaria transmission. Large scale mapping of Plasmodium falciparum infection prevalence, such as that undertaken by the Malaria Atlas Project, relies on opportunistic assemblies of data on infection prevalence arising from thousands of P. falciparum parasite rate (PfPR) surveys conducted worldwide. Variance in these data is driven by both signal -the true underlying pattern of infection prevalence -and a range of factors contributing to 'noise' -including sampling error, diff ering age ranges of subjects, and diff ering parasite detection methods. Whilst the former two have been addressed in previous maps, the eff ect of diff erent diagnostic methods used to determine PfPR in diff erent studies has not. In particular, the majority of PfPR data are based on positivity rates determined by either microscopy or rapid diagnostic test (RDT), and it is known that the sensitivity and specifi city of these approaches are not equivalent. There is therefore a need for a method to quantitatively compare and adjust RDT-and microscopy-based prevalence estimates to a common standard prior to use in mapping. Here we estimate a relationship between RDT-and microscopy-derived PfPR using paired RDT and microscopy outcomes from sub-Saharan African populations. A total of 19 Demographic and Health Survey datasets from subSaharan Africa provide child diagnostic test results derived using both RDT and microscopy for each individual. We aggregated these prevalence estimates across administration zones (ADMIN1) and fi tted a Bayesian probit regression to the microscopy-versus RDTderived prevalence relationship. We employed an errors-in-variables approach to acknowledge sampling error in both the dependent and independent variable. In addition to the diagnostic outcome, several factors were extracted from the datasets in order to analyze their eff ect on observed malaria prevalence, sensitivity and specifi city. These factors included: RDT type, fever status, recent ACT treatment, and estimated local population malaria prevalence. We present results of stratifi ed regression and analysis of variance analyses to establish the infl uence of these factors on measured prevalence, sensitivity and specifi city. The fi tted models can be applied to RDT-derived PfPR data to convert them to an estimate of the prevalence expected using microscopy, thereby standardizing the dataset and improving the signal-to-noise ratio. Additionally, our results provide insight into factors that infl uence the observed prevalence, sensitivity and specifi city of diff erent diagnostic techniques. Background Kenya launched its second National Malaria Strategy with a notably ambitious vision for a "malaria free Kenya", but malaria remains a major health problem among communities in Lake Victoria in western Kenya. Materials and methods We conducted three cross-sectional surveys during the dry (January 2012) and two consecutive wet seasons (August 2012 and August 2013) among communities residing in three diff erent settings in Lake Victoria: (1) along the mainland coast (Ungoye: population ~2,000); (2) on a large island (Mfangano: population ~25,000); and (3) on small islands (Takawiri, Kibuogi, and Ngodhe: population ~700 each). The prevalence of malaria infections and G6PD defi ciency was analyzed by geography and/or season. Results Overall, parasite rates (PRs) as determined by microscopy (18.9% vs 18.4%), rapid diagnostic test (RDT; 36.9% vs 30.8%) and PCR (31.1% vs 28.5%) were higher in the dry season than in the wet seasons with characteristic age distribution. In both seasons, PRs were highest in the coast, then in the large island and lowest on the small islands. The highest prevalence by RDT during the dry season was observed in Ungoye: 54.4% in age group 0-5 years old, 68.4% in 6-10, 55.3% in 11-15, 13.2% in 16-30 and 11.3% in >30. Species-specifi c prevalence by PCR was 29.3% for Plasmodium falciparum, 8.5% for P. malariae, and 2.1% for P. ovale in the dry season, and 26.6%, 7.2%, and 3.3%, respectively, in the wet seasons. Prevalence of mixed infections was 8.3% and 7.1% Malaria Journal 2014, Volume 13 Suppl 1 http://www.malariajournal.com/supplements/13/S1 in the dry and wet seasons, respectively. P. vivax was not detected by microscopy or PCR in any survey. Signifi cant seasonal fl uctuations in PRs were observed among children and young adolescents on islands but not in the coast. Among all settings, G6PD defi ciency was found in 12.1% of males and 2.1% of females. No signifi cant correlation between G6PD defi ciency rates and PRs was observed in any settings. Conclusions Variation in malaria prevalence refl ects the diff erent dynamic of malaria transmission between the islands and the coast of Lake Victoria. Our results provide baseline data for the planned feasibility study of malaria elimination on islands in Lake Victoria.
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Comparing community P. falciparum infection prevalence measured via microscopy versus rapid diagnostic test
Results
The isolation of an in vitro active bifl avonoid from Campnosperma panamense (Anacardiaceae, IC 50 = 480 nM, P. falciparum K1), led us to the development of simplifi ed synthetic analogs (MR series) with improved pharmacological and pharmacokinetic profi les. Notably one of them (MR70) exhibits a partial in vivo antimalarial activity with a reduction of parasitaemia by 45% on day 4. Conclusion We described here the fi rst substituted fl avone showing an in vivo antimalarial activity in a murine model. This scaff old should be promising in the fi ght against malaria. To understand its mechanism of action, we are currently running diff erential metabolomics analysis by solid NMR (coll. Pr. J. I. Namer, Strasbourg, France) to highlight some potential impact on Plasmodium metabolic pathways.
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Increasing human mobility and the expansion of global air travel has resulted in increasing movements of vector-borne diseases. Despite having eliminated malaria and being classed as 'malaria-free' , European, North-American and some Asian countries still see tens of thousands of cases each year through importation. This work focuses on the assembly of a global database of nationally reported statistics on imported malaria cases over the past 10 years. We highlight the substantial spatial, temporal and demographic heterogeneities that exist between countries and explore the variations in origins of cases, risk groups and malaria types. Further, we examine the possibility of using a range of widely reported country statistics on socioeconomic factors, travel data and geospatial data on malaria risk to predict the number of cases each country is likely to see through construction of a multivariate statistical model. Results show strong predictive power in determining diff erences and driving factors between countries in rates of imported malaria. Such a model has the potential to be used for guiding interventions to reduce rates of malaria importation, as well as for future scenario analyses for strategic planning. Here we address the issue of the possible interplay between host genetic variation and the risk of acquiring Plasmodium falciparum drug-resistant strains. The involvement of human genetic variation as a possible co-factor in the selection and spread of P. falciparum drug resistance is a new tool in the study of malaria and possibly of other infectious diseases. The driving hypothesis of this approach is that parasite drug resistance could be aff ected both by ethnicity and human variability in the genes encoding for enzymes that metabolise antimalarials (cytochrome P450 liver enzymes). Understanding if parasite drug sensitivity is infl uenced and possibly modulated by human diversity can contribute to a better knowledge and control of the spread of drug resistance. So far, few studies have addressed this strategic issue. To explore this hypothesis we carried out an association analysis on 506 human/P. falciparum DNA samples from adult asymptomatic subjects belonging to three sympatric ethnic groups of Burkina Faso, an area of hyperendemic malaria in West Africa. Here we report that the prevalence of chloroquine-resistant infections (pfcrt 76T and/or pfmdr1 86Y) diff ers among sympatric ethnic groups, being higher in Mossi and Rimaibé compared to Fulani (OR: 2.24; 1.27-3.92; P = 0.007). Moreover, the human CYP2C8*2 variant, known to determine a poor drug metaboliser phenotype, is associated with P. falciparum chloroquine-resistant infections (OR: 1.66; 1.13-2.43; P = 0.008). The results strongly suggest that human genetic variation aff ects the dynamics of selection of parasite drug-resistance. We strongly believe that these observations are of general interest and may have important implications in public health. Complex and widespread with about 90% of the global burden in subSaharan Africa, malaria remains a signifi cant health problem. Malaria vaccines have the chance to make signifi cant inroads, with RTS,S vaccine candidate as the most advanced candidate. However, the need for a highly effi cacious, long-lasting vaccine is still unmet. Continued support for a repertoire of tools for Plasmodium falciparum is needed. A blood-stage vaccine is desirable to deal with morbidity and mortality secondary to P. falciparum infection, and thus would be a valuable strategy in the fi ght against malaria. The P. falciparum serine repeat antigen-5 formulated with aluminum hydroxyl gel (BK-SE36) is a blood-stage malaria vaccine candidate. The processing of SERA5 is believed to mediate parasite egress from the infected red blood cell. Field studies show good correlations of anti-SERA antibodies to malaria protection against blood parasitemia, malaria symptoms and severe disease. A Phase 1a trial demonstrated its safety and immunogenicity in malaria naïve Japanese adults. A Phase 1b trial was conducted in the malaria endemic area of Northern Uganda to assess the vaccine's safety and immunogenicity. BK-SE36 had an acceptable safety and immunogenicity profi le. Posttrial, Stage 2 subjects were age-matched to 50 control individuals to compare malaria episodes 130-365 days post-second vaccination. Logrank test reveal signifi cant diff erences in BK-SE36 vaccinees vs control group in time-to-fi rst episodes with parasitemias ≥5,000/μL and those with ≥5,000/μL + fever (protective effi cacy for the latter is 72%, P < 0.01). BK-SE36 vaccinees have fewer multiple malaria episodes with high parasitemia. We also observed that the antibody titers against SE36 were boosted after episodes of natural infection. Above results show that BK-SE36 could provide some protection against natural P. falciparum infection until 1 year post-second vaccination.
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clinical trials at multiple sites across Africa. Modeling and simulation have been used to predict the public health impact (PHI) of RTS,S but previous exercises had access to limited trial data and did not provide country-specifi c results. PHI is sensitive to many assumptions including vaccine profi le and underlying country specifi c inputs.
Materials and methods
We simulated the numbers of cases and deaths averted by RTS,S if rolled out in each of 43 malaria endemic countries in sub-Saharan Africa. Predictions were made for diff erent transmission profi les, diff erent levels of access to care for malaria cases, and four diff erent immunisation schedules, with varying initial effi cacies and decay rates of vaccine effi cacy. Country-specifi c predictions were made via weighted averages over the database of predictions, with weights estimated from country-specifi c data. These included prevalence data from the Malaria Atlas Project, access to care from Demographic and Health Surveys, country level estimates of patient adherence and system compliance, immunization coverage from UN/WHO, and demographic projections from the UN. Sensitivity analysis was carried out to determine the robustness of the predictions of average impact and main drivers of uncertainty in these. Results and conclusions A pre-erythrocytic vaccine is unlikely to completely protect vaccinated individuals against malaria disease but overall PHI will probably compare favourably with that of other vaccines in routine programs. Currently only short follow up of RTS,S Phase III trial data is available and thus uncertainty in overall PHI remains mainly driven by uncertainty in the vaccine profi le, especially in the rate of decay of the protective eff ects. There will be considerable variation between countries in PHI, with the main driver of this variation being the underlying levels of transmission and disease burden. Background The use of single-dose primaquine to block transmission of Plasmodium falciparum malaria is complicated by variation in glucose-6-phosphate-dehydrogenase (G6PD) activity and potentially cytochrome P450 2D6 (CYP2D6). G6PD defi ciency determines primaquine safety while the CYP2D6 metabolizer phenotype may determine primaquine effi cacy by infl uencing metabolism into active metabolite(s). While there is evidence that the CYP2D6 metabolizer phenotype infl uences primaquine effi cacy against P. vivax hypnozoites, there is currently no evidence for CYP2D6 in relation to its gametocytocidal activity in P. falciparum. Materials and methods We used samples from a dose-fi nding study where Ugandan children with uncomplicated malaria were randomized to receive artemether-lumefantrine together with a placebo or 0.1, 0.4 or 0.75 mg/kg primaquine. Gametocyte carriage was determined by Pfs25 QT-NASBA on nucleic acids from 50 μL blood samples that were subsequently used for CYP2D6 assays. Using the QuantStudio 12K Flex system and 32SNP OpenArray as well as copy number variation (CNV) assays, CYP2D6 genotypes were determined for the available DNA samples. Results 247 out of 468 individuals included in the trial were successfully genotyped for CYP2D6. CYP2D6 phenotypes were predicted from the genotypes with the classical method, yielding phenotypes for all but 13% of genotyped individuals. The number of poor metabolizers (PM) and ultrarapid metabolizers (UM) in this Ugandan cohort was very low (2% for both), while 25% (62/247) of the children were intermediate metabolizers (IM). Gametocyte prevalence on day 7 after initiation of treatment with 0.4 mg/kg primaquine was 7% (2/28) in extensive metabolizers (EM) or UM compared to 38% (3/8) in IM and 100% (1/1) in PM (P = 0.009). The same pattern was not present in the other treatment arms.
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CYP2D6 intermediate metabolizer status could slow down
Conclusions
The number of PM is low in our study population and does not allow a fi rm conclusion on its impact on gametocyte clearance following primaquine. IM had longer persisting gametocytes after receiving 0.4mg/kg primaquine suggesting that the transmissionblocking eff ect of low-dose primaquine may be infl uenced by CYP2D6 activity. Larger studies that include mosquito infectivity outcomes are needed to fi rmly establish whether CYP2D6 variations impact the utility of primaquine for P. falciparum transmission reducing activities.
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Latter-stage preclinical developmental work on PL69/DM1157 David Peyton The drug class we originally termed 'Reversed Chloroquines' has been assessed, via SAR, to select a candidate for preclinical evaluation. Such molecules were originally designed to function like the late-20th century Gold-standard, chloroquine, but with an appendage that intentionally inhibits resistance. Thus, PL69/DM1157 was subjected to screening, beginning with potency against many laboratory-adapted strains of chloroquine-resistant P. falciparum and in vivo effi cacy in mice. PL69/DM1157, having structural features in common with chloroquine, might have cardiac eff ects, so we evaluated for hERG interaction, but more rigorously in a guinea pig electrocardiogram model. The results indicated the cardiac safety to be similar to chloroquine. Academic collaborators have subjected PL69/DM1157 to clinical isolates of highly resistant P. falciparum, as well as to P. vivax strains. A chloroquine-resistant strain of P. falciparum was also subjected to PL69/DM1157 pressure for over two years in an unsuccessful attempt to increase IC 50 . The project has now progressed through off -target evaluations, in vitro toxicity assessments, and rat preclinical toxicity tests. The molecule has been synthesized under GLP certifi cation, without chlorinated solvents or any chromatographic steps to >99% purity, at suffi cient scale to permit fi nal toxicity evaluation in a second species, as well as in a Phase-I clinical trial, using the same batch. This work also demonstrates how collaboration between a university and a start-up company can be an alternative pathway to bring a neglected-disease drug through the necessary drug development steps. The experience gained through this and other malaria work has enabled the company to begin collaborative work on drug-resistant bacterial diseases as well. Bangladesh is a malaria hypo-endemic country sharing borders with India and Myanmar. ACT remains quite successful in Bangladesh. An increase of heritable artemisinin resistant malaria parasites on the Thai-Cambodia border and subsequently the Thai-Myanmar border is worrisome. K13 propeller gene (PF3D7_1343700 (PF13_0238) mutations have been linked to both in vitro artemisinin resistance and in vivo slow parasite clearance rates and therefore proposed as a marker of artemisinin resistance. We evaluated if mutations seen in Cambodia have emerged in Bangladesh where ACT use is now standard for over a decade. Samples were obtained from P. falciparum infected malaria patients from Upazila Health Complexes (UHC) of seven endemic districts of Bangladesh. These districts included Khagrachhari (Matiranga UHC), Rangamati (Rajsthali UHC), Cox's Bazar (Ramu and Ukhia UHC), Bandarban (Lama UHC), Mymensingh (Haluaghat UHC), Netrokona (Durgapur and Kalmakanda UHC) and Moulvibazar (Srimongol and Kamalganj UHC). Out of 296 microscopically positive P. falciparum samples, 271(91.6%) were confi rmed by both real-time PCR and nested PCR to have pure infection. Nested PCR of the K13 gene amplifi ed 253 (93.4%) samples. After ClustalW alignment and Jalview analysis, we initially found three non-synonymous mutations (A578S, W470C, and Y604H) in Bangladeshi clinical isolates. The A578S mutation was confi rmed and lies adjacent to the C580Y mutation, the major mutation observed in Cambodia, and based on computational modeling should have a signifi cant eff ect on tertiary structure. We conclude that novel mutations that may confer artemisinin resistance are present in certain districts of Bangladesh.
P71
Mutations in
P72
Pharmacovigilance for single low-dose primaquine: a practical approach Eugenie Poirot 1,2 , Andy Stergachis
Establishing and strengthening pharmacovigilance in resource-limited settings provides a valuable opportunity to identify, quantify and address pertinent safety concerns regarding the use of single low-dose (SLD) primaquine. While it is understood that primaquine causes dosedependent hemolysis in glucose-6-phosphate dehydrogenase (G6PD) defi cient individuals with P. falciparum and P. vivax malaria, the extent of this risk when using low doses of primaquine remains to be defi ned. Prospective pharmacovigilance methods are needed to confi rm or refute these safety concerns that have likely hindered the uptake of the new WHO policy for SLD primaquine. Pharmacovigilance in resource-limited settings is challenging, especially when attempting to identify unknown or poorly understood adverse drug reactions over weeks of follow-up. In contrast, the objectives of a pharmacovigilance program for SLD primaquine are specifi c, measurable, and attainable within a short time frame. The nadir of primaquine-induced hemolytic anemia, measurable by hemoglobin concentrations, has been shown to occur on or near day 7. Thus, it is expected that adverse drug reactions related to primaquine can be captured within a week of drug administration by active surveillance methods involving patient follow-up. Furthermore, dark urine is a characteristic sign of acute hemolytic anemia, an easily identifi able and documentable symptom of hemolysis. Numerous pharmacovigilance eff orts are ongoing, supporting individual countries in the collection of standardized SLD primaquine safety data. These eff orts seek to establish the expected fall in hemoglobin from baseline levels before treatment to levels seven days post-treatment and include G6PD testing and recording of adverse events using standard data collection instruments. Each participating in-country program or study site aims to collect data on 100-400 subjects depending on malaria endemicity and expected G6PD prevalence. We plan to collate data across these countries in a global database of individual patient data, contributing to the evidence-base for benefi t-risk assessments of SLD primaquine. As other 8-aminoquinoline drugs such as tafenoquine come to market, we will be faced with related safety concerns of dose-dependent hemolysis in G6PD-defi cient individuals. Active pharmacovigilance and the establishment of a standardized database for SLD primaquine not only provide opportunities to harmonize eff orts, address unanswered questions regarding the safe use of SLD primaquine, and assist programs planning widespread roll-out of SLD primaquine in routine malaria case management they can also serve as a common platform for other current and future pharmacovigilance needs. The methods used in these eff orts and the composition of this database will be described.
Background Malaria is a major cause of death and has been one of the strongest selective forces on the human genome selecting variants that infl uence pathogenesis, host response and may protect against disease severity [1, 2, 3] . Previous studies suggest the association between malaria and red blood cell (RBC) glucose-6-phosphate dehydrogenase (G6PD) and pyruvate kinase (PK) defi ciencies in humans [4] . This study focuses on RBC-pathogen interactions and the eff ect of these two enzymatic defi ciencies on parasite development. Proteomic information from Plasmodium infection is scarce, and proteomes of both G6PD-and PK-defi cient RBC and from parasites growing in these cells have not yet been characterized. We performed a proteomic study to detect the relative abundance of proteins from both G6PD-and PK-defi cient RBC, and also from Plasmodium infecting these cells. It will provide key information about malaria dynamics, but also about enzyme defi ciencies causing important haemolytic anaemia. Furthermore, it will contribute to a better understanding of host-parasite interactions. Materials and methods P. falciparum 3D7 was maintained in continuous synchronous cultures. Invasion ratios and maturation ratios were determined. Samples were prepared for proteomic analysis by FASP and GelC-MS. LC-MS and CID-MS/MS of peptides were carried out by nano-RP-LC-MS/MS. Data were analyzed for identifi cation of peptides and quantifi cation through comparison of normalized peak area/intensity of each identifi ed peptide.
Results Only results from parasite proteome are available so far. There was an over-expression of defensive molecules against oxidative stress Malaria Journal 2014, Volume 13 Suppl 1 http://www.malariajournal.com/supplements/13/S1
(heat shock proteins and chaperones) in parasites growing in G6PD-defi cient RBC, and an under-expression of global proteins (mostly proteins involved in haemoglobin catabolism and traffi cking/RBC remodelling) in parasites growing in PK-defi cient RBC. The study will still look into infected RBC proteome and assess the infl uence of these alterations in the putative protective eff ect against malaria.
Background Malaria elimination is one of the important health priorities for the government of the I.R. of Iran. In 2010, the National Strategic Plan for Malaria Elimination was ratifi ed by the High Council for Health and the Governor Generals of three malarious provinces (i.e. Sistan & Balouchestan, Hormozgan and Kerman) were assigned as the core persons for leading the program, dealing with potential challenges, administrative arrangements and fi nancial support. The number of malaria reported cases were 11,000. Material and methods In this survey, malaria surveillance data including weekly, monthly, and web based university reports during the last fi ve years (2009-2013) along with administrative documents related to the malaria program were investigated. In addition, all malaria related research projects and proposals from 2010 to 2014 were reviewed. Findings Given the fact that the malaria elimination program has received strong political commitment from the government, and also academic members and national research centers have been involved in the program, the country has been witnessing tremendous success in tackling malaria across the country. The majority of research topics have shifted to the applied proposals with direct involvement of provincial and district malaria focal points. Moreover, insecticide resistance management, molecular/microscopic monitoring of effi cacy of antimalarial and expansion of foci approach to the remote areas are main achievements of this intersectoral collaboration. The great achievements, so far, include: Kerman province now is free from falciparum malaria, reducing local malaria cases to 442 at the country level and reduction of active and residual active foci from 1040 to 369. Conclusions Political will has had a strong role in accelerating malaria elimination at the country level. Mutual collaboration of research centers and academia with provincial/district health authorities also has had a crucial role in shifting basic research to the targeted malaria applied projects in line with national priorities. Malaria rapid diagnostic tests (RDTs) are now considered an acceptable alternative for parasite based diagnosis in the absence of adequate quality microscopy. Selection of the most appropriate RDT among the sheer number of tests available commercially has long been a challenge, raising the need to objectively assess and compare test performance. In order to facilitate RDT procurement and stimulate improvement of the quality of RDTs, methods were developed for the collection and characterization of geographically diverse, malaria infected clinical blood specimens to set up a specimen bank for the evaluation of malaria RDTs, as part of the WHO Malaria RDT Product Testing programme. Parasite positive samples were diluted to low (200 p/ul) and higher (2000 p/ul) parasite densities and used to provide comparative data on the performance of RDT lots submitted by manufacturers. Only samples containing a single species and producing consistent antigen quantifi cation results were eligible for inclusion in the WHO Malaria Specimen Bank. At both 200 and 2000 p/μl, a large variation in antigen concentrations was found, especially for P. falciparum HRP2, and to a lesser extent for pLDH and aldolase (both in P. falciparum and P. vivax samples); a trait that was independent of geographical origin. Possible reasons for this include the duration of infection at the time of blood collection and principally, diff erences in antigen expression between diff erent isolates and stages of parasites. It is critical that performance evaluation panels are standardised at a parasite density being not only clinically relevant but also being close to the test detection limit to detect diff erences in test performance. Given the signifi cant fl uctuation in antigen concentrations at a given parasitaemia, appropriate sample sizes are required to cover that range and challenge the RDTs at the low end of this range of antigen concentrations. Antigen concentrations that are relevant for improvements in target sensitivity for RDTs are still to be determined for samples with parasite densities below 200 p/μl. As plans for malaria eradication continue, a vaccine targeting Plasmodium vivax is of major importance due to the fact that it is the most widely distributed human malaria parasite in the world and the most diffi cult to eliminate due to its ability to hide in the liver forming hypnozoites. Malaria liver-stage vaccines are one of the leading strategies and the only approach that has demonstrated complete, sterile protection in clinical trials. We have developed vaccine candidates using platforms suitable for human use, consisting of virus-like particles (VLPs), chimpanzee adenovirus (ChAd63) and modifi ed vaccinia Ankara (MVA) containing malaria pre-erythrocytic antigens, and several novel challenge models using transgenic mousemalaria P. berghei parasites expressing P. vivax antigens that permit the assessment of vaccine effi cacy in small animal models, thus providing a suitable platform for vaccine development in non-endemic countries and permitting the progress of vaccines that rely on assessment of effi cacy rather than measurement of immunogenicity, in the absence of a conclusive correlate of protection.
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Development of a
We present results of two leading malaria vaccine candidates, a universal vivax circumsporozoite antigen (PvCSP) and the thrombospondinrelated adhesion protein (PvTRAP) to create recombinant adenovirus, MVA and a platform consisting of VLPs to enhance effi cacy of our malaria vaccines. All have been tested using transgenic parasites expressing the P. vivax CSP VK210, VK247 and TRAP, thus permitting the assessment of protective effi cacy in various mouse strains and yielding important information to address cross protection against CSP using a challenge with VK210 or VK247 parasites in mice vaccinated with homologous, heterologous or chimeric CSP antigens. Our studies indicate that our vaccines are able to induce outstanding T-cell responses and antibody titers that can protect against a stringent challenge with high doses of fully virulent transgenic parasites in mice. Our groups are currently committing a substantial eff ort in developing further transgenic parasites to allow the discovery of new vaccine candidates able to aff ord protection. Malaria infections often consist of more than one strain of the same parasitic species. Understanding the within-host competition between these various strains is essential to understanding the evolution and epidemiology of drug resistance in malarial infections. The infection process and the competition between strains involve complicated biological processes that are explained by various hypotheses. Mathematical models tested against experimental data provide quantitative measures to compare these hypotheses and enable us to discern the actual biological processes that contribute to the observed dynamics. We use a group of models against experimental data on rodent malaria to test various hypotheses. Such quantitative measures, in understanding rodent malaria, can be considered as a step towards understanding within-host parasite dynamics. Our work presented here demonstrates how confronting mathematical models with data allows the discovery of subtle and novel interactions between hosts and parasites that would be impractical to do in an experiment and allows the rejection of hypotheses that are incorrect. It is our contention that understanding the forces controlling within-host parasite dynamics in well-defi ned experimental model is a necessary step towards understanding these features in natural infections. Malaria is a global health problem that causes signifi cant mortality and morbidity, with more than 1 million deaths per year caused by P. falciparum. Most antimalarial drugs face decreased effi cacy due to the emergence of resistant parasites. Therefore, the eff orts to improve current treatments are focused on the identifi cation of new antimalarial drugs displaying novel mechanisms of action. To increase the probability of success to identify compounds active against all relevant parasite drug targets, phenotypic assays have been used to screen large compound libraries against P. falciparum blood stages. At GSK, 2M compounds were screened and 13500 confi rmed hits (TCAMS-Tres Cantos Antimalarial Set) were selected which inhibited P. falciparum growth with IC 50 s below 2 μM. In order to select chemotypes with a presumptive novel mechanism of action, an early profi ling is carried out which involves several phases:
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Discovering antimalarials with a diff erential mode of action
1. In the fi rst phase, compounds are tested against a wide panel of P. falciparum strains with well characterized genetic linkage to drug resistance to establish which series had no cross-resistance with already known antimalarial compounds. Panel includes laboratory strains as well as clinical isolates. 2. In a second phase, compounds are tested using functional assays to identify those molecules interfering with parasite pathways that are targets of already known antimalarials (electron transport, folate and isoprenoid). Both mitochondrial electron transport and pyrimidine biosynthesis inhibitors are identifi ed using transgenic parasites overexpressing Saccharomyces cerevisiae DHODH. Addition of proguanil to cultures restores cytochrome bc1 blockage but not DHODH inhibition. Antifolates are identifi ed by supplementing the growth medium with folic acid and, similarly, inhibitors of the isoprenoid biosynthesis pathway by adding geranyl geranyol or isopentenyl pyrophosphate, which shifts the IC 50 of inhibitors of these pathways. 3. Finally compounds are subjected to hematin polymerization assays to establish the interference with this essential pharmacological target of malaria parasites. New scaff olds with novel modes of action can be selected using these approaches avoiding the interference with pathways which are known to develop resistance. This strategy has already been succesful and our current antimalarial pipeline is based on scaff olds displaying new mechanisms of action. Chemoproteomics and chemical genomics eff orts are being used to decipher new MoA. [2] . IRS is most eff ective when using DDT, a persistent organic pollutant [3] . Insecticide Treated Wall Lining (ITWL) or Netlon® is a slow release technology that combines the advantages of LLIN and IRS. Current commercial wall linings are produced using labour intensive fabric weaving methods. This study explored the eff ectiveness of inexpensive monofi lament mesh linings produced by extruding insecticide impregnated polyethylene and poly(ethylene-co-vinyl acetate) (EVA) directly into a net format. Materials and methods Polyethylene and EVA were extruded with pyrethroids (deltamethrin and alphacypermethrin) and organophosphates (ca. 0.5 wt.% insecticide) respectively through a dye to form monofi lament meshes. Scanning Electron Microscopy (SEM) and Confocal Fluorescence Microscopy (CFM) was used to characterize the presence of insecticide on the surface of the monofi laments. Effi cacy testing was done using standard WHO bioassay tube tests. Results For Netlon® to be eff ective, the insecticides have to be available on the monofi lament surface since they are contact poisons. SEM and CFM micrographs show that pyrethroids are present and evenly distributed on the surface of the monofi lament mesh. The WHO eff ectiveness criterion is a mortality exceeding 80% after 24 hours following a 30 minute exposure of An. arabiensis mosquitoes to test samples. The pyrethroid impregnated mesh samples achieved 100% mortality in this test even after 24 months of storage. Samples impregnated with organophosphates failed to achieve the WHO criterion. Poor performance of the organophosphate insecticides in the EVA matrix was probably due to the high solubility of these insecticides in this polymer. Conclusions Monofi lament polyethylene mesh impregnated with pyrethroid insecticides was successfully produced by a simple direct extrusion technique. It is an inexpensive method for the production of slow-release polymer-based wall linings. Laboratory effi cacy tests suggest that this ITWL technology may be a potential substitute for IRS and it may also complement LLIN.
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Development of an insecticide impregnated polymer wall lining for malaria vector control
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Background Atovaquone is a safe, eff ective antimalarial drug that inhibits the mitochondrial electron transport chain (mtETC) of P. falciparum. Clinical resistance is conferred by SNPs in cytochrome b. Although multiple non-synonymous SNPs can be selected in vitro, thus far clinical resistance is limited to amino acid substitutions at position 268 (e.g., Y268S). We are investigating additional mechanisms by which some isolates of P. falciparum became extremely resistant to atovaquone and other mtETC inhibitors by selecting for in vitro resistance to the dihydroorotate dehydrogenase (DHODH) inhibitor DSM-1. Methods We characterized isolates from patients that failed treatment in atovaquone phase II studies by using a series of chemotypes that target mitochondrial function. We defi ned their structureactivity relationships and observed broad resistance (5-10,000 fold in atovaquone), suggesting that cytochrome b mutations alone are not suffi cient. We tested this by selecting for DSM-1 resistance in atovaquone-susceptible and resistant parasites (paired patient admission and recrudescent isolates). Following selection, the parasites were sequenced for mutations in cytochrome b, DHODH and other candidate mtETC genes. Results The extreme atovaquone resistance phenotype accompanies a high-grade resistance to all mtETC inhibitors tested including DSM-1. Selection studies of atovaquone susceptible parasites rapidly generated resistance in vitro to both atovaquone and DSM-1 alone (10x IC 50 concentration) yet atovaquone resistant parasites could only generate low resistance to DSM-1 (2x IC 50 ), and one population reverted the aa268 mutation to wild-type to cope with DSM-1 pressure. Furthermore, we successfully recapitulated the clinical Y268S mutation in vitro in TM90-C2A, the pre-treatment parent for TM90-C2B. Conclusions Cytochrome b mutations are not suffi cient to explain extreme mtETC resistance, and selective pressure on the DHODH enzyme revealed that the Y268S cytochrome b mutation incurs a fi tness cost on the parasite that cannot be overcome under DSM-1 drug pressure, yet resistance was easily obtained in atovaquone-susceptible parasites. This suggests that resistance to atovaquone (Y268S) and DSM-1 are mutually incompatible. Selection of the Y268S mutation in TM90-C2A indicates that the parasite genetic background is critical in the selection of clinical atovaquone resistance, since selection attempts in multiple other strains results in mutations in positions other than aa268. Further studies are required to determine the impact of this phenotype on the development of new mitochondria-targeted drugs.
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Preliminary studies of biosynthesis of heme O and heme A in intraerythrocytic stages of P. falciparum Raquel Simão-Gurge Background Intermediates of the isoprenoid metabolism can bind to heme groups. Heme is critical and its derivatives, heme O and heme A, are the main compounds of aerobic respiration. They are synthesized by farnesylation of heme groups by "heme O synthase" (HOS or Cox10) and "heme A synthase" (HAS or Cox15). The identifi cation of heme O and heme A and characterization of enzymes involved in their synthesis are important for exploring the possible products biosynthesized by the parasite derived from the MEP pathway. Importantly, hemes A and O are essential molecules for numerous living organisms, since they are critical components of the mitochondrial electron transport chain, catalyzing the reduction of O 2 to H 2 O. Additionally, the heme group is an important target of drugs such as artemisinin and quinolines. Methods The characterization of heme O in P. falciparum was done by two diff erent methods using metabolic labeling with [ 3 H] FPP and [ 14 C] Glycine followed by extraction and separation through a C18 column permitting to observe heme O as well as heme B biosynthesis. The plasmodial orthologs of HOS (PfCox10) and HAS (PfCox15) genes were identifi ed by their homology to HOS and HAS enzymes from other organisms. We then genetically tagged both genes with GFP and HA coding sequences and visualized transfectants by fl uorescence microscopy. Results and conclusion We observed production of heme O and heme B in blood stage parasites. Visualization tagged PfCox10 and PfCox15 suggested that both enzymes were most probably localized in the mitochondria although PfCox10 presented an unusual extension at its N-terminus.
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Protection from liver-stage malaria is dependent on a fi ne balance between the number of infected hepatocytes and eff ector CD8 + T cells Alexandra Spencer, Rhea Longley, Anita Gola, Teresa Lambe, Adrian Hill University of Oxford, Oxford, UK Malaria Journal 2014, 13(Suppl 1):P83
Background Since the demonstration of sterile protection aff orded by injection of irradiated sporozoites, CD8 + T cells have been shown to play a signifi cant role in protection from liver-stage malaria. This is, however, dependent on the presence of an extremely high number of circulating eff ector cells, thought to be necessary to scan, locate and kill infected hepatocytes in the short time that parasites are present in the liver. To this day very little is known about the T cell response to malaria in the liver, therefore we have utilized an adoptive transfer system in mice to elucidate the kinetics of CD8 + T cell mediated protection following sporozoite challenge. Materials and methods Balb/c mice were immunized with viral vectors expressing the immunodominant epitope from P. berghei CS protein, Pb9, to induce high numbers of antigen specifi c CD8 + T cells that were transferred into recipient mice. By CFSE labeling cells we were able to track CD8 + T cell migration into the liver and recruitment of cells into division by fl ow cytometry in the days following sporozoite challenge. Results and conclusions To our surprise we did not detect active recruitment of CD8 + T cells into the liver or liver draining lymph nodes in the early days following sporozoite challenge. Cell division was also not required for protection as divided cells were only detected 3 days after challenge. In addition CD8 + T cells were shown to only require 24 hours to locate and kill infected hepatocytes. By titrating the number of transferred cells and sporozoites we discovered a threshold of CD8 + T cell mediated protection dependent on both the number of infected hepatocytes and circulating CD8 + T cells. When mice were challenged with only a small number of sporozoites, not enough CD8 + T cells were reactivated, while injection of higher numbers of sporozoites led to better survival. In the absence of detectable changes in the CD8 + T cell response at the macroscopic level, we are currently establishing a liveimaging model to study the interplay between eff ector CD8 + T cells and sporozoites in the liver. Background Iron is an essential micronutrient required by all living organisms including malaria parasites (Plasmodium spp.) for many biochemical reactions, especially growth and multiplication processes. Therefore, the malaria parasites needs to take up the iron from outside or/and inside the parasitized red blood cells (PRBC). Iron chelators are widely used for treatment of thalassemia-related iron overload and also inhibit parasite growth at levels which are non-toxic to mammalian cells.
Materials and methods
The inhibitory eff ect of 1-(N-acetyl-6-aminohexyl)-3-hydroxypyridin-4-one (CM1) and green tea extract (GTE) on the growth of malaria parasite P. falciparum was investigated compared with standard chelators including desferrioxamine (DFO), deferiprone (DFP) and deferasirox (DFX). A fl ow cytometric technique was used to enumerate the PRBC stained with SYBR Green I fl uorescent dye. Labile iron pool (LIP) was assayed using calcein-acetomethoxy (Calcein-AM) fl uorescent method. Results The IC 50 values of DFO, GTE, CM1, DFX and DFP against P. falciparum were 14.09, 21.11, 35.14, 44.71 and 58.25 μM, respectively. Importantly, CM1 was more eff ective in reducing LIP level in the P. falciparum culture than DFP (P < 0.05). Conclusions CM1 and GTE exhibit anti-malarial activity. They could interfere with uptake of exogenous iron or deplete intracellular labile iron in malaria parasites, leading to inhibition of their growth.
Background Mass screening and treatment campaigns have had limited success in curbing malaria transmission, possibly as a consequence of the high prevalence of subpatent infections that are missed using the currently available fi eld based diagnostic tools. It has been shown that subpatent malaria infections are more likely to occur in households where patent infections are identifi ed suggesting that it may be possible to employ a more focal approach to treatment campaigns using sentinel cases as markers for the presence of a subpatent reservoir. However, it is not known which defi nition of sentinel case to rely on for initiation of treatment would provide optimal coverage of the parasite reservoir. Materials and methods In a low endemic and highly heterogeneous malaria transmission setting in the western Kenyan highlands we conducted a focal screening and treatment campaign as part of a larger cluster randomized trial. All consenting individuals under 15 years old and febrile adults residing within all households within the defi ned clusters were tested for malaria with a rapid diagnostic test (RDT). Temperature and blood spots on fi lter paper were collected from all household members (N = 2083), regardless of RDT result. The parasite reservoir was determined using nested polymerase chain reaction and gametocyte nucleic acid sequence-based amplifi cation; multiple defi nitions of a sentinel case were assessed to determine which identifi ed the largest proportion of parasitized individuals in the total population. Results We observed signifi cant household clustering of parasite carriage with a 23.5% (95% CI 21.6-25.3%) increased probability of being positive for malaria by PCR if another member of the same household was also parasitaemic. Sentinel populations of RDT-positive i) febrile individuals, ii) children <5 years of age, iii) children <15 years of age and iv) children <15 years of age and all febrile individuals have variable levels of coverage. However, even with the best approach (iv), only 36.0% to 80.0% of parasitized households corresponding to 46.6% to 90.1% of parasitized individuals were identifi ed. Successful coverage was related to background parasitaemia and was improved considerably if compounds surrounding sentinel cases were included in the intervention. Conclusions Despite strong clustering at the household level, targeting compounds with parasite positive sentinel cases does not achieve complete coverage of the parasitaemic reservoir. Even in the most optimistic scenario, 20% of households or 10% of the parasitaemic reservoir will go undetected when relying on conventional malaria diagnostics in sentinel populations.
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Large diff erences in variability for genes associated with antimalarial drug resistance between samples from Tanzania and Ethiopia Lemu Golassa Background Changes in antimalarial drug policy lead to selection of the most successful parasite clones. In spite of a change to Artemisinin Malaria Journal 2014, Volume 13 Suppl 1 http://www.malariajournal.com/supplements/13/S1 S36 Combination Therapy (ACT), we have earlier shown a low degree of variability for the chloroquine resistance marker pfcrt in samples of Plasmodium falciparum from Ethiopia with 100% carrying the crucial K76T variant [1] . Materials and methods The study material was collected in the Shalla district, Oromia, Ethiopia, and in diff erent parts of Tanzania. Genetic polymorphisms in the genes pfmdr1 and pfubp1 were analysed by PCR and nucleotide sequence determinations. Results A surprising fi nding was that a majority of Ethiopian isolates carried the wild type variant of pfmdr1. The majority of samples from diff erent regions of Tanzania were wild type for both pfcrt and pfmdr1. Analysis of a variable linker region in pfmdr1 showed substantial variation in samples from Tanzania, but minimal variation in samples from Ethiopia. The variable part consists of consecutive NDN residues. The dominating variant in Ethiopians was 7/2/9 and 7/2/10 in Tanzania. The same pattern was seen for a variable part of the pfubp1 gene, where all Ethiopian samples were identical to 3D7. In 19 Tanzanian samples only 8 were identical to 3D7 with 5 other variants. A polymorphism at codon 1528, detected previously in Kenyan samples [2] was found in 2 Tanzanian samples. Conclusions While the presence of the mutant variant of pfcrt in the Ethiopian samples can be explained by continued use of chloroquine in Ethiopia for treatment of P. vivax, the selection of wild type pfmdr1 could be a consequence of using ACT for treatment of P. falciparum. In general, the variability in both studied genes was greater in Tanzania than in Ethiopia. There are no data yet to link the variability in pfubp1 to effi cacy of ACT. References often considerably less than 60% effi cacy against clinical malaria [2] resulting in a need for other approaches that may enhance this partial protection. One such approach is the use of viral vectors in a heterologous prime-boost regime with the aim of inducing a T-cell response. Previous studies have shown high levels of immunogenicity by using a chimpanzee adenovirus (ChAd63) followed by an attenuated vaccinia virus (modifi ed vaccinia Ankara (MVA)) to deliver the preerythrocytic antigen, multiple epitope string with thrombospondinrelated adhesion protein (ME-TRAP) [3] . Materials and methods We undertook a phase IIb study to assess the effi cacy and further evaluate the immunogenicity and safety of such a vaccination strategy involving 120 healthy adults in Dakar, Senegal. Volunteers received either ChAd63 followed by MVA, both containing ME-TRAP, or two shots of rabies vaccine. After the second immunization, all volunteers were given short-lasting antimalarials. The time taken to fi rst malaria infection was measured by PCR and compared between the two groups. IFN-γ production by T-cells, seen as an integral component of liver stage protection, was measured by ELISpot at various points throughout the trial. Intracellular cytokine staining was used to determine the relative proportions of CD4 + and CD8 + T-cells secreting IL-2, IFN-γ and/or TNFα in response to peptide stimulation. Results Peak immunogenicity was identifi ed 7 days after boosting vaccination with MVA ME-TRAP, at a geometric mean of 1266 spots per million PBMC (95% CI 985-1504) compared with 87 spots per million (95% CI 57-117) among control vaccinees, P < 0.0001. While this vaccine strategy is aimed at enhancing the cellular response towards the liver stage, TRAP-specifi c IgG responses were also measured by ELISA and were modest in magnitude. Effi cacy analysis using time to PCR positive is ongoing, however this vaccine approach has shown an acceptable safety profi le and good, potent cellular immunogenicity in this semiimmune population. Background The changing temperature and rainfall patterns associated with climate change are expected to alter the distribution of environmental suitability for malaria transmission in West Africa.
Materials and methods
We use a mechanistic model of disease transmission to investigate the eff ects of climate change on village scale hydrology, entomology, and disease transmission. This highly detailed model explicitly simulates water pools that serve as mosquito breeding sites, the life cycle of individual mosquito agents, and the transmission of the malaria parasite between human agents. Results We simulate current malaria conditions ranging from the very low transmission region bordering the Sahara to the higher transmission Savanna zones, focusing on areas with high sensitivity to increases in vectorial capacity. We then consider predictions of future climate, and assess the impact these changes would on malaria transmission. Conclusions The use of this mechanistic model allows us to translate projected changes in temperature and rainfall into changes in vectorial capacity and malaria transmission rates. The binding domain of Duff y protein (DBP-II) is a leading vaccine candidate of Plasmodium vivax. In order to develop a successful vivax malaria vaccine based on DBP-II, the antigenic diversity and also naturally occurring functional antibodies to diff erent PvDBP-II variant types in the various populations must be known. To defi ne whether the polymorphisms in PvDBP-II infl uenced the nature of functional antibody responses, this investigation was designed to evaluate naturally acquired antibodies to fi ve circulating variant forms of DBP-II antigens in infected individuals with P. vivax living in hypoendemic areas in Iran. Sequence diversity of pvdbp-II gene was performed in 63 Iranian P. vivax isolates collected during 2008-2012. The sequencing analysis showed twenty two single nucleotide polymorphisms in PvDBP-II, resulting in 16 diff erent haplotypes among the Iranian P. vivax isolates. Five of 16 genetically distinct variants were expressed in E. coli, and anti-DBP-II responses were measured in P. vivax-infected individuals (n = 202). Also, by performing immune-depletion ELISA experiments, antibody responses to the conserved sites of all fi ve allelic forms were evaluated using the corresponding and non-corresponding patients' sera (n = 20). ELISA results revealed that naturally acquired anti-PvDBP-II IgG were recognized all fi ve expressed variant forms with no statistically diff erence (P > 0.05, Cochran's Q test). The antibody depletion experiments also showed presence of the cross-reactive antibody responses to heterologous variants of PvDBP-II in Iranian individuals who were infected with distinct allelic forms of the PvDBP-II. Finally, all fi ve examined variant forms of DBP-II were expressed transiently on the surface of COS-7 cells to determine whether people exposed to vivax malaria acquire antibodies that have the ability to block erythrocyte cytoadherence to PvDBP-II. The anti-DBP-II IgG block heterologous and homologous expressed DBP-II function, indicating that the protective immunity against PvDBP-II binding is not strain specifi c. In conclusion, the present results indicate that the single variant of PvDBP-II is adequate to be included in a PvDBP-II-based vaccine.
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Remodelling of the erythrocyte cytoskeleton during P. falciparum merozoite invasion Elizabeth Zuccala Background Red blood cells are remarkably resilient, fl exible and dynamic structures. These properties are required for their passage through small capillaries and are imparted by the cytoskeleton, a network of proteins that underlies and links to the cell membrane. To successfully invade, the blood stage malaria parasite must induce drastic changes to the structure of the target erythrocyte, including the formation of a tight junction and a new cellular compartment, the parasitophorous vacuole. These key modifi cations involve the infolding of the red blood cell membrane, membrane fusion and fi ssion events and the secretion of parasite proteins into the host. While detailed cellular descriptions of merozoite invasion have been achieved over the past few decades, comparatively little is known about the molecular basis of how the host cell responds to parasite entry. It has long been suggested that erythrocyte ATP and a kinase are required The docking results indicate that heparin binds more eff ectively with high affi nity as compared to heparan sulphate with some common interacting residues [2] . These common residues can play an important role in rosetting and will aid in the designing of inhibitors specifi c to the interactions between DBLα and heparin or heparan sulphate would be important in malaria treatment.
Conclusions Thus such an analysis may lead to the development of novel interference strategies to block red blood cell invasion and provide protection against malaria and provide an insight into the complexities of host parasite interactions. References
